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ABSTRACT OF DISSERTATION

ZINC DEFICIENCY AND MECHANISMS OF ENDOTHELIAL CELL
DYSFUNCTION
Atherosclerosis is a chronic inflammatory disease thought to be initiated by
endothelial cell dysfunction. Research described in this dissertation is focused on the role
of zinc deficiency in endothelial cell activation with an emphasis on the function of the
transcription factors nuclear factor-κB (NF-κB), peroxisome proliferator activated
receptor (PPAR), and the aryl hydrocarbon receptor (AhR), which all play critical roles in
the early pathology of atherosclerosis. Cultured porcine aortic vascular endothelial cells
were deprived of zinc by the zinc chelator TPEN and/or treated with the NF-κB inhibitor
CAPE or the PPARγ agonist rosiglitazone, followed by measurements of
PPARα expression, cellular oxidative stress, NF-κB and PPAR DNA binding, COX-2
and E-selectin expression, and monocyte adhesion. Cellular labile zinc deficiency
increased oxidative stress and NF-κB DNA binding activity, and induced COX-2 and Eselectin gene expression, as well as monocyte adhesion in endothelial cells. CAPE
significantly reduced the zinc deficiency-induced COX-2 expression, suggesting
regulation through NF-κB signaling. PPAR can inhibit NF-κB signaling. Zinc
deficiency down-regulated PPARα expression and PPAR DNA binding activity in
endothelial cells. Zinc deficiency compromised PPARγ transactivation activity in PPARγ
and PPRE co-transfected rat aortic vascular smooth muscle cells. Furthermore,
rosiglitazone was unable to inhibit the adhesion of monocytes to endothelial cells during
zinc deficiency. Most of these effects of zinc deficiency could be reversed by zinc
supplementation. An in vivo study utilizing the atherogenic LDL-R-/- mouse model
generally supported the importance of PPAR dysregulation during zinc deficiency. LDLR-/- mice were maintained for four weeks on either zinc deficient or zinc adequate diets.
Half of the mice within each zinc group were gavaged daily with rosiglitazone during the
last stage of the study. Selected inflammation and lipid parameters were measured. The
anti-inflammatory properties of rosiglitazone were compromised during zinc deficiency.
Specifically, rosiglitazone induced inflammatory genes (MCP-1) in abdominal aorta only
during zinc deficiency, and adequate zinc was required for rosiglitazone to down-regulate
pro-inflammatory markers such as iNOS in abdominal aorta of the mice. Rosiglitazone
significantly up-regulated liver IκBα protein expression only in zinc adequate mice.

Plasma data also suggest an overall pro-inflammatory environment during zinc deficiency
and support the concept that zinc is required for proper anti-inflammatory or protective
functions of PPAR. Zinc deficiency also altered PPAR-regulated lipid metabolism in
LDL-R-/- mice. Specifically, zinc deficiency increased plasma total cholesterol, and nonHDL (VLDL, IDL and LDL)-cholesterol. Plasma total fatty acids tended to be increased
during zinc deficiency, and rosiglitazone treatment resulted in similar changes in fatty
acid profile in zinc deficient mice. FAT/CD36 expression in abdominal aorta was
upregulated by rosiglitazone only in zinc-deficient mice. In contrast, rosiglitazone
treatment markedly increased LPL expression only in zinc-adequate mice. These data
suggest that in this atherogenic mouse model treated with rosiglitazone, lipid metabolism
can be compromised during zinc deficiency. AhR is another transcription factor involved
in the development and homeostasis of the cardiovascular system. Cultured porcine
aortic endothelial cells were exposed to the AhR ligands PCB77 or beta-naphthoflavone
(β-NF) alone or in combination with the zinc chelator TPEN, followed by measurements
of the AhR responsive cytochrome P450 enzymes CYP1A1 and 1B1. Zinc deficiency
significantly reduced PCB77- induced CYP1A1 activity and mRNA expression, as well
as PCB77 or β-NF-induced CYP1A1 protein expression, which could be restored by zinc
supplementation. These data suggest that adequate zinc is required for the activation of
the AhR-CYP1A1 pathway. Impairment of the AhR pathway presents an additional
mechanism by which zinc deficiency negatively affects transcription factor function and
homeostasis of the vascular system. Taken together, zinc nutrition can markedly
modulate the pathogenesis of inflammatory diseases such as atherosclerosis.
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Chaper 1. Introduction
1.1

Background

1.1.1 Atherosclerosis/Inflammation
Atherosclerosis, a progressive disease of large arteries, is one of the most
common underlying causes of death in western countries, accounting for about 50 % of
all deaths [1, 2]. Atherosclerosis is a chronic inflammatory condition that results from
interaction between modified lipoproteins, monocyte/macrophages, T lymphocytes, and
the normal cellular components of the arterial wall such as endothelial cells, and smooth
muscle cells. This inflammatory process can lead to the development of complex lesions,
or fibrous plaques, which protrude into the arterial lumen and narrow the vessel. Plaque
rupture results in the formation of thrombus and the subsequent acute clinical events of
myocardial infarction and stroke [1, 2]. Atherosclerosis is associated with endothelial
cell dysfunction and apoptosis [3]. The vascular endothelium, with its intercellular tight
junctions, functions as a selectively permeable barrier between blood and tissues. It also
plays important roles in the physiological and pathological processes of vessels via both
sensory and executive functions. By generating effector molecules, the endothelium
regulates vascular tone, inflammation, thrombosis, and vascular remodeling [2].
Epidemiological studies have revealed multiple risk factors for atherosclerosis, including
factors with a strong genetic component, and environmental factors, such as lifestyle and
nutritional factors [1-3].

1.1.2 Zinc deficiency
Zinc deficiency has been identified as a risk factor for atherosclerosis [3, 4]. As a
frequent condition in human populations, zinc deficiency affects about one third of the
world’s population and contributes to 1.4 % of all deaths worldwide [3, 4]. Although
acute zinc deficiency is rare nowadays in industrialized countries, marginal zinc
deficiency is still relatively common [3]. Zinc deficiency can happen when zinc intake is
inadequate or zinc is poorly absorbed, when zinc loss from the body is increased, or when
the body’s requirement for zinc increases [4]. Some dietary factors, which are present
1

mainly in vegetable products, such as phytates (including inositol hexaphosphates and
pentaphosphates), can strongly inhibit zinc absorption [5]. Certain disease states, like
diabetes and alcoholism, can increase urinary loss of zinc and are thus responsible for the
total body zinc decrease [4, 6]. Other physiological and pathological conditions, such as
reproduction, rapid growth, and acute inflammation, all increase the organism’s demand
for zinc and will lead to zinc deficiency if the demand is not fulfilled [4, 7]. Symptoms
of zinc deficiency include growth retardation, delayed sexual maturation, immune
dysfunction, delayed wound healing, diarrhea, dermatitis, pregnancy complications,
behavioral abnormalities and eye lesions [4, 8].

1.1.3 Zinc physiology
Zinc plays multiple important functions in biological systems. As a component of
biomembrane, zinc is distributed among the major membrane protein fractions and is
critical for membrane structural integrity and stability [9, 10]. Membrane-bound zinc
can regulate activities of membrane-bound enzymes, protect biomembrane against lipid
peroxidation, and constitute a pool of rapidly available zinc [4, 9]. Zinc is also necessary
for maintaining normal cytoskeletal structure [4]. Furthermore, zinc plays structural and
catalytical roles in hundreds of enzymes and thousands of “zinc-finger” protein domains
[11]. Zinc has antioxidant functions in that it 1) stabilizes macromolecules against
radical-induced oxidation; 2) competes with pro-oxidant metals (iron and copper) for
binding sites, thus decreasing their ability to form free radicals; 3) inhibits excess
production of free radicals by biological systems; 4) is an essential part of the
intracellular and extracellular antioxidant enzyme superoxide dismutase (SOD), and 5)
induces the potent antioxidant metallothionein, which is an efficient hydroxyl radical
scavenger [4, 11-13]. In addition, zinc-protein interactions have been found to regulate
signal transduction [4, 11].
Most intracellular zinc is bound to structural and/or regulatory proteins such as
metallothionein, resulting in very low concentrations of metabolic active (labile) zinc,
estimated at picomolar to nanomolar range [14]. Cellular zinc homeostasis is tightly
regulated by the levels of zinc uptake, cellular storage, trafficking, and elimination [11,
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14]. There are basically two categories of membrane zinc transporters involved in zinc
uptake and elimination: Zip (Zrt- and Irt-like proteins (SLC39A)) and ZnT (solute-linked
carrier 30 (SLC30A)). Zip transporters mediate extracellular zinc uptake and
intracellular vesicle zinc release into the cytoplasm, therefore increasing intracellular
zinc, while ZnT transporters promote zinc efflux from cells to extracellular space or into
intracellular vesicles, thereby lowering intracellular zinc [15, 16]. The mechanisms of
Zip and ZnT mediated zinc transport are not well understood. Zip-mediated zinc uptake
could be a process of facilitated diffusion driven by a zinc concentration gradient. ZnT
transporters could function as secondary active transporters or antiporters since cellular
extrusion of zinc and vesicular zinc deposition occur against a zinc concentration gradient
[16]. Coordination of intracellular zinc storage and trafficking mainly depends on the
cysteine-rich protein metallothionein. Metallothionein is an intracellular transition metal
binding protein that is critical for regulation of homeostasis of essential metals such as
zinc and copper, and detoxification of heavy metals such as cadmium [17].
Metallothioneins provide intracellular zinc binding sites with one metallothionein
molecule capable of binding totally seven Zn2+ atoms, with the metal detoxification
related α domain binding four Zn2+ atoms via 11 cysteines and the physiologically
relevant β domain binding three Zn2+ atoms via 9 cysteines [16, 18]. Behaving as zinc
chaperones, metallothioneins play a donor/acceptor role for zinc-binding motifs in
metalloproteins, such as various metalloenzymes and transcription factors, thereby can
activate or deactivate them [14, 16]. Furthermore, metallothioneins play an important
role in protecting against cellular stressors, such as carbon-centered radicals, reactive
oxygen species (ROS), and reactive nitrogen species (RNS) [16]. As free radical
scavengers, metallothioneins can efficiently scavenge most types of ROS, including
hydroxyl radical (•OH), superoxide (O2• –), hydrogen peroxide (H2O2), peroxynitrite
(ONOO–) and nitric oxide (NO) [19, 20]. Despite the high affinity of metallothionein for
zinc, the metal can be released from and rebind to the protein, which is regulated by
cellular redox state (the so called “metallothionein redox cycle”). Specifically, oxidation
of the thiolate cluster of metallothionein by various cellular oxidants can release zinc
from metallothionein, forming metallothionein-disulfide, which in turn can be reduced by
cellular reducing agents, such as glutathione, thereby restoring zinc binding to the protein
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and reconstitute metallothionein. In general, the thermodynamically stable zinc binding
makes metallothionein an ideal intracellular zinc reservoir, and the redox regulation of
zinc mobilization enables metallothionein to maintain cellular zinc homeostasis [17].

1.1.4 Zinc and redox signaling
The unique chemical nature of zinc determines its central position in the cellular
redox signaling network. Zinc by itself is redox inert but it can create a redox active
environment when binding to a sulfur ligand. Oxidation of the sulfur ligand mobilizes
zinc, while reduction of the oxidized ligand promotes zinc binding. Thus the reversible
oxidation of the sulfur ligand is coupled to the reversible zinc release from the protein,
providing redox control over zinc availability. These cysteine-rich zinc binding proteins
are thereby called “ redox zinc switches” that are controlled by concentrations of both
oxidants and zinc [14, 18]. Some of these protein “redox zinc switches” are redox
sensors, in which zinc release is coupled to protein conformational changes that affect
enzymatic activity, molecular chaperone activity, and binding interactions, with no
known function of the released zinc. Other protein “redox zinc switches” are redox
transducers, in which redox signals are converted to zinc signals via binding of the
released zinc to other proteins and modulating signal transduction, metabolic energy
generation, mitochondrial function, and gene expression. Metallothionein is one example
of such redox transducers, which, together with its apoprotein, thionein, functions to
control zinc availability, redistribute cellular zinc, and interconvert redox and zinc signals
[18]. To maintain redox homeostasis, it is essential to keep tight control of zinc
availability, because both inadequate and excessive cellular zinc will elicit oxidative
stress [18].
Cellular labile zinc deficiency leads to a condition of oxidative stress [4]. A low
zinc status alters the expression and activity of anti-oxidant enzymes and other
components of the biological oxidant defense system. In addition, zinc deficiency rapidly
increases cellular global oxidants, including ROS and RNS, which will lead to tissue
oxidative damage, increasing DNA, protein, and lipid oxidation. The mechanisms of zinc
deficiency-induced oxidative stress are not clear. Possible mechanisms could be 1)
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compromised roles of zinc as a physiological antioxidant, 2) impaired mitochondrial
function that increases ROS formation, possibly by altered expression of certain
respiratory chain components, and 3) altered expression and/or activity of ROS/RNS
metabolizing enzymes [4]. On the other hand, excessive zinc that overwhelms the
buffering capacity of the cellular zinc homeostasis system also induces oxidative stress
by increasing mitochondrial ROS generation, etc. [18]. Therefore, zinc exhibits antioxidant properties only in an intermediate range of physiological and possibly also
pharmacological concentrations [18].

1.1.5 Zinc deficiency and cell signaling
Zinc deficiency-induced oxidative stress affects cell signaling, including zinc
finger transcription factors, such as peroxisome proliferator activated receptors (PPARs),
and other oxidative stress sensitive transcription factors, such as activator protein-1 (AP1) and nuclear factor-κB (NF-κB) [4, 18]. Oxidative stress impairs the DNA-binding
activity of zinc finger transcription factors by oxidizing the thiol groups in cysteine
residues, which coordinate zinc in the reduced form, followed by alteration of the
secondary structure of the transcription factor proteins. In this way, oxidative stress can
reduce transcription of genes regulated by zinc finger transcription factors [4]. The
PPARs are ligand-activated transcription factors belonging to the steroid/thyroid
hormone nuclear receptor superfamily [21, 22]. PPARs regulate the expression of genes
involved in lipid and glucose homeostasis, inflammatory response, and cell
differentiation [21, 23]. There are three isotypes of PPAR: PPARα, PPARβ/δ, and
PPARγ [21]. Upon ligand binding, PPAR heterodimerizes with another nuclear receptor
retinoid X receptor (RXR) and binds to peroxisome proliferators response elements
(PPREs) located in the promoter regions of PPAR regulated genes and transactivates
these genes [21, 23]. Since both PPAR and RXR have two zinc fingers in their DNA
binding domains [22, 24], zinc deficiency could impair the DNA binding and
transactivation activities of the PPAR:RXR transcription factor complex. There is
evidence that zinc deficiency can compromise PPARα and γ signaling in vascular
endothelial cells [25, 26].
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Zinc deficiency-induced oxidative stress activates AP-1, mainly through
activation of the stress-responsive mitogen-activated protein kinases (MAPKs) JNK and
p38 [4]. The effect of zinc-deficiency on NF-κB activation is cell line specific. Earlier
work in our lab has shown that zinc-deficiency can increase NF-κB DNA binding activity
in porcine vascular endothelial cells compared to zinc-adequate cells [10]. Similar
observations were obtained in mast cells and mononuclear cells as well [27, 28].
However, in some other cell types, such as rat glioma C6 cells, human T-helper type-0
(Th0) malignant lymphoblastoid HUT-78 cells, human neuroblastoma IMR-32 cells, and
3T3 fibroblasts, zinc deficiency has been described to decrease NF-κB DNA binding
activity [29-32]. Although the cytosolic events in NF-κB signaling, i.e., IκBα
phosphorylation and subsequent ubiquitinization and degradation, are activated by
increased oxidative stress in the zinc deficient cells, zinc deficiency-induced tubulin
depolymerization impairs translocation of the activated NF-κB into the nucleus. This can
result in inhibition of transactivation of NF-κB regulated genes and thus may explain in
part the inhibitory effects of zinc deficiency on NF-κB activation [4, 30]. The reason for
the cell specific effects of zinc deficiency on NF-κB activity is not clear [3]. Since NFκB is the major transcription factor responsible for up-regulating pro-inflammatory
genes, such as vascular adhesion molecules [33], it is necessary to investigate the
influence of endothelial zinc status on the expression of adhesion molecules and other
NF-κB target genes. This type of study has not been reported so far and thereby becomes
one focus of the current in vitro study utilizing vascular endothelial cells as the research
model.

1.1.6

PPAR/TZD
PPARs have anti-inflammatory properties by negative cross-talk with major

inflammatory pathways including NF-κB, AP-1, nuclear factor of activated T cells
(NFAT), signal transducer and activator of transcription-1 (STAT-1), and
CAAT/enhancer binding protein β (C/EBPβ) (Fig. 1.1) [21]. PPARα can repress NF-κB
and AP-1 pathways via interactions with p65 subunit of NF-κB and c-Jun of AP-1,
respectively [34]. Similarly, PPARγ can inhibit the NF-κB pathway by physically
6

interacting with p50 and p65 subunits of NF-κB [35]. PPARα agonists, such as fibrates,
induce IκBα (an inhibitor of NF-κB) expression, providing an additional mechanism for
the inhibition of NF-κB by PPARα and the anti-inflammatory properties of PPARα
agonists [36]. PPARγ agonists, such as troglitazone, a member of the thiazolidinedione
(TZD) class, inhibit c-fos induction, which constitutes an additional mechanism for the
inhibition of AP-1 by PPARγ [37].
TZDs are synthetic PPARγ ligands that have been clinically used to treat type II
diabetes [38-40]. In addition to their metabolic effects of improving insulin sensitivity
and glycemic control, TZDs have direct anti-atherogenic effects of increasing NO
bioavailability, inhibiting leukocyte/endothelial cell interaction, repressing vascular
smooth muscle cell proliferation and migration, and promoting macrophage cholesterol
efflux [39]. Animal studies have shown that TZDs can decrease blood pressure, repress
left ventricular hypertrophy and atherosclerotic lesion development, and protect the
myocardium from ischemia/reperfusion injury [38]. TZDs have also been shown to
affect surrogate markers of vascular disease, such as dyslipidemia, hypertension,
microalbuminuria, visceral fat, levels of adiponectin, C-reactive protein (CRP),
plasminogen activator inhibitor type I (PAI-I), and matrix metalloproteinases (MMPs),
carotid intima-media thickness, coronary stent restenosis, and delay progression of
atherosclerosis in different patient groups, including type II diabetic patients [39, 40].
The anti-atherogenic effects of TZDs can be due to their insulin-sensitizing anti-diabetic
effects. Because TZDs decrease insulin resistance, they may also improve other insulin
resistance associated abnormalities, thereby decrease the morbidity and mortality of
cardiovascular diseases [38, 40]. One the other hand, by modulating gene expression in a
wide variety of cells, TZDs can also benefit the cardiovascular system by means
independent of their anti-diabetic effects [38]. Despite the favorable effects of TZDs on
cardiovascular surrogate markers, adverse effects of TZDs, including weight gain, fluid
retention (edema), and the potential to exacerbate or precipitate heart failure can
considerably limit the use of TZDs, especially in heart failure patients [41]. Recent
clinical trails suggest that treatment with TZDs increased the risk for development of
congestive heart failure in prediabetic and type II diabetic patients [41, 42]. The effects
of TZDs on overall cardiovascular outcome still await better-designed future study. The
7

effects of zinc nutritional status on the anti-inflammatory and anti-atherogenic properties
of TZDs in an atherogenic animal model have not been studied. These questions are of
particular interest to us and led to the current in vivo study utilizing the atherosclerosis
prone LDL-receptor deficient (LDL-R-/-) mouse model treated with the PPARγ specific
agonist rosiglitazone.

1.1.7 AhR/PCB
The effect of endothelial zinc status on the aryl hydrocarbon receptor (AhR)
pathway is another focus of the research presented in this dissertation. AhR is a ligandactivated transcription factor which belongs to the Per-ARNT-Sim (PAS) family of basichelix-loop-helix (bHLH) transcription factors [43]. AhR ligands include planar
polycyclic and halogenated aromatic hydrocarbons, such as polychlorinated biphenyls
(PCBs), and various classes of plant-derived chemicals [44, 45]. Prior to activation, AhR

exists in the cytoplasm in association with heat shock protein (HSP)90, HSP90 accessory
proteins, and immunophilin-like proteins such as XAP2/ARA9/AIP and p23 [45].
Ligand binding to the AhR promotes its dissociation from this chaperone complex and
exposure of its nuclear localization signals, and its subsequent translocation to the
nucleus where the ligand-activated AhR heterodimerizes with the aryl hydrocarbon
nuclear translocator (ARNT) [46, 47]. The AhR:ARNT complexes then bind to the aryl
hydrocarbon, xenobiotic, or dioxin response elements (AhREs, XREs, DREs) located in
the promoter regions of target genes and transactivate the expression of a battery of genes
involved in the metabolism (activation or detoxification) of endogenous and foreign
compounds, oxidative stress response, cell cycle control, and apoptosis. These AhRregulated genes are collectively called the AhR gene battery [44, 47, 48]. AhR-generated
cellular oxidative stress responses can elicit metabolic events ranging from physiological
to adaptive, and to toxicological processes. The mechanisms involved include 1)
induction of genes associated with inflammation, such as tumor necrosis factor α (TNFα)
and cyclooxygenase-2 (COX-2); 2) regulation of prooxidant and antioxidant enzymes
that generate or detoxify ROS, such as xanthine oxidase/xanthine dehydrogenase
(XO/XDH) and SOD; and 3) induction of cytochrome P450 enzymes, such as the CYP1
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family [44]. P450s catalyze the monooxygenation of various endogenous and exogenous
compounds and normally reduce diatomic oxygen to water efficiently with little release
of ROS. However, when uncoupling of the P450-substrate complex with the NADPHP450 oxidoreductase and/or cytochrome b5 happens, the activated oxygen is released
from the enzyme as either O2• –, or H2O2, or other forms of ROS without substrate
modification [44, 48, 49]. In addition to the well characterized roles of the AhR in
inducing Phase I and Phase II metabolizing enzymes and mediating xenobiotic signaling
[45, 50], the AhR has recently been shown to be involved in multiple molecular cascades
leading to the modulation of cell proliferation, differentiation, and apoptosis, thereby
playing important regulatory roles in the development and homeostasis of various organ
systems including the cardiovascular system [45, 47, 51, 52]. Although the DNA binding
activity of AhR does not seem to require zinc [53], zinc deficiency can inhibit the DNA
binding activity of SP1 [53], a zinc figure transcription factor that cooperates with
AhR:ARNT in regulating CYP1A1 gene expression [54]. Since zinc plays multiple roles
in maintaining homeostasis of the cardiovasculature [55] and is also required for normal
cardiovascular development [56], it is intriguing to find out how zinc status could
influence the AhR pathway. Little is known on how zinc nutritional status could
modulate certain AhR ligands, such as the toxic environmental contaminants
polychlorinated biphenyls (PCBs), and thus modulate a biological outcome in the
cardiovascular system.
PCBs, a class of halogenated aromatic hydrocarbons with different numbers and
positions of chlorine substitution on the biphenyl moiety, are widespread persistent
organic environmental contaminants because of their chemical stability and previous
extensive industrial use [57]. The use of PCBs has been banned in most countries since
the late 1970s and the PCB levels in environmental samples are beginning to decline [57,
58]. PCBs are resistant to degradation by metabolism. Being lipophilic, they tend to
bioaccumulate and biomagnify, and can be found at all levels of the food chain [57, 58].
PCBs have systemic toxicity in laboratory animals, wildlife species, and the human
beings through activation of the AhR [59]. The major source of human exposure to PCBs
is food [60]. The toxicological effects of PCBs on human health include endocrine
disruption, immune dysfunction, defects in reproduction and neurological development,
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as well as carcinogenesis [60]. PCBs can also contribute to the development of
inflammatory diseases, such as atherosclerosis [61]. Coplanar PCBs, such as PCB 77, can
cause endothelial cell dysfunction by disrupting endothelial barrier function, increasing
cellular oxidative stress, activating NF-κB, and mediating production of the inflammatory
cytokine IL-6. As an AhR agonist, PCB 77 induces these inflammatory responses mostly
via the AhR-CYP1A pathway [62].
In general, zinc has potent anti-inflammatory and anti-atherogenic properties. As
an anti-oxidant, zinc can prevent the oxidative modifications of LDL thereby inhibit one
of the main mechanisms of atherosclerosis [63]. Zinc can also modulate the activity of
lipase. Zinc deficiency reduces the activity of lipoprotein lipase, which plays an
important role in clearance of triglyceride-rich lipoproteins, and is correlated with
increased serum triglycerides concentrations [64], which is a risk factor of atherosclerosis
[65]. In addition, zinc participates in the regulation of blood pressure and in the
pathogenesis of hypertension, and loss of zinc homeostasis can be the cause of high blood
pressure. [66]. Zinc deficiency could thus constitute a risk factor for atherosclerosis by
increasing LDL oxidation, elevating plasma triglycerides levels, and inducing
hypertension [3, 4, 63]. Epidemiological studies have shown that low dietary zinc intake
and low serum zinc levels are associated with an increased prevalence of coronary artery
disease and its associated risk factors, such as hypertriglyceridemia and hypertension, in
certain populations [67, 68]. Furthermore, significantly lower than control (normal aortas
from subjects died in accidents or from causes other than atherosclerosis) concentrations
of zinc were also found in atherosclerotic plaques of abdominal aorta in patients deceased
with ischemic heart disease and acute myocardial infarction [69]. So far only a few
molecular and cellular mechanisms have been proposed on how zinc deficiency could
contribute to the pathogenesis of atherosclerosis, including activation of NF-κB and
related inflammatory responses, activation of caspase-mediated apoptosis, and changes in
NO signaling [3]. It is important to further explore the mechanisms involved in zinc
deficiency induced pro-inflammatory events in endothelial cells and the vascular system
as well, and to clarify how these events can contribute to the development of
atherosclerosis. The new findings described in this dissertation will add to the existing
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knowledge of the micronutrient zinc and zinc-deficiency-related adverse effects on
biological systems, especially the cardiovascular system, and will contribute to provide a
scientific basis for the prevention of atherosclerosis by zinc nutritional intervention.

1.2

General Hypothesis and Specific Aims
The general hypothesis of the research described in this dissertation is that zinc

deficiency can lead to endothelial cell inflammatory responses as well as proinflammatory events in whole animal through modulation of the NF-κB, PPAR, and AhR
signaling pathways. To test this hypothesis, the following specific aims were proposed:
Specific Aim 1: To test the hypothesis that zinc deficiency induces endothelial
cell inflammation by activating the NF-κB pathway and inhibiting the PPAR pathway.
Specific Aim 2: To test in vivo the hypotheses that zinc deficiency compromises
proper PPARγ function and alters PPARγ-regulated inflammatory responses and lipid
metabolism. The LDL-R-/- mouse model was used to demonstrate the zinc-dependent
anti-inflammatory properties and favorable lipid effects of rosiglitazone in early stages of
atherosclerosis.
Specific Aim 3: To test the hypothesis that zinc deficiency can modulate PCB77induced endothelial cell inflammation.
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Figure 1.1. The anti-inflammatory properties of PPARα and γ
By interfering with the major inflammatory pathways, such as NF-κB, AP-1, NFAT,
C/EBPβ, and STAT-1, PPARα and γ can inhibit the inflammatory responses. NF-κB,
nuclear factor-κB; AP-1, activator protein-1; NFAT, nuclear factor of activated T cells;
C/EBPβ, CAAT/enhancer binding protein β; STAT-1, signal transducer and activator of
transcription-1 (adapted from Blanquart C, J Steroid Biochem Mol Bio, 2003. 85: 26773).

Copyright © Huiyun Shen 2008
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Chaper 2. Compromised Anti-inflammatory Responses and Intensified Proinflammatory Responses in Vascular Endothelial Cells during Zn
Deficiency
2.1

Synopsis
Zinc has anti-inflammatory properties and is crucial for the integrity of vascular

endothelial cells. We have shown that zinc deficiency can increase cellular oxidative
stress and subsequently activate NF-κB. Mechanisms of endothelial cell inflammation
during zinc deficiency are not well defined. The current study focuses on the hypothesis
that during zinc deficiency, pro-inflammatory signaling pathways, such as NF-κB, are
activated; meanwhile anti-inflammatory signaling pathways, such as PPAR, are
compromised. Porcine vascular endothelial cells were made zinc deficient by chelation
with the membrane permeable zinc chelator TPEN. Zinc deficiency increased oxidative
stress and NF-κB DNA binding activity, and induced COX-2 and E-selectin gene
expression, as well as monocyte adhesion in cultured endothelial cells. These changes
were reversed by zinc supplementation to the endothelial cell cultures. The NF-κB
inhibitor caffeic acid phenethyl ester (CAPE) significantly reduced the zinc deficiencyinduced COX-2 protein expression, suggesting regulation through NF-κB signaling.
PPAR can inhibit NF-κB signaling. Zinc deficiency down-regulated PPARα expression
in cultured endothelial cells. PPAR DNA binding activity was also compromised during
zinc deficiency. Furthermore, the PPARγ agonist rosiglitazone was unable to inhibit the
adhesion of monocytes to endothelial cells during zinc deficiency, an event which could
be reversed by zinc supplementation. A transient transfection-luciferase assay confirmed
that adequate zinc is required for rosiglitazone-induced PPARγ activation to transactivate
target genes. These data demonstrate the importance of zinc in proper PPAR function
and the requirement of zinc to prevent inflammatory responses, suggesting that zinc
deficiency might be involved in the pathogenesis of atherosclerosis.
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2.2

Introduction
The development of atherosclerosis is of multiple causes and involves the

interaction of genetics, lifestyle, nutrition and other environmental risk factors [1].
Atherosclerosis is believed to begin with endothelial cell activation or dysfunction, which
is associated with a series of early changes that lead to fatty streak lesion formation. The
changes include oxidative modifications of low density lipoprotein (LDL), up-regulation
of endothelial adhesion molecules, recruitment of monocytes to the activated
endothelium, accelerated migration of monocytes into the arterial wall, and
differentiation of monocytes into macrophages; all events can lead to accelerated lesion
progression and ultimately to plaque rupture and thrombosis [1]. There is evidence that
zinc nutrition can modulate early phases of atherosclerosis [70].
As an essential trace element, zinc plays multiple roles in biological systems,
including structural, catalytic, and regulatory functions [71, 72] . Zinc is required for the
maintenance of the normal structure of membrane and cytoskeleton [4]. Zinc also plays
both catalytic and structural roles in hundreds of enzymes and thousands of “zinc finger”
protein domains. Through zinc/protein interactions, zinc also plays regulatory functions
in cellular signaling, in the architecture of protein complexes, and in redox control [4,
11]. Cellular zinc homeostasis is maintained largely by membrane zinc transporters and
by the intracellular zinc storage and trafficking protein metallothionein [11, 15, 16].
There is evidence showing that zinc deficiency is related to the pathogenesis of
atherosclerosis. For example, low dietary zinc intake and low serum zinc levels were
found to be associated with increased prevalence of coronary artery disease and its
associated risk factors, such as hypertension and hypertriglyceridemia, in certain
populations [67, 68]. In addition, lower concentrations of zinc were found in
atherosclerotic plaques of abdominal aortas in deceased patients with ischemic heart
disease and acute myocardial infarction compared with normal aortas [69]. The
mechanisms of zinc deficiency in the development of atherosclerosis remain to be
elucidated. Zinc may play a critical role as a potent antioxidant and anti-inflammatory
agent [10, 28]. For example, zinc deficiency increases cellular oxidative stress [10, 31],
and in turn activates oxidative stress-sensitive transcription factors such as NF-κB and
AP-1 in endothelial cells [10] and 3T3 cells [31], respectively.
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Zinc has also been shown to modulate the function of PPARs [25, 26, 73].
PPARs are ligand-activated transcription factors that heterodimerize with RXR and bind
to PPRE to regulate expression of genes involved in lipid and glucose metabolism,
inflammatory response, and cellular differentiation [21]. There are three PPAR isoforms,
i.e. PPARα, PPARβ/δ, and PPARγ and they are expressed in all major cell types of
atherosclerotic lesions [74]. PPARs possess anti-inflammatory properties by inhibiting
major pro-inflammatory pathways, such as NF-κB and AP-1. In this way, PPARs
modulate the expression of adhesion molecules as well as cytokines/chemokines and their
receptors, which in turn inhibits inflammatory responses [21]. Since the DNA binding
domains of both PPAR and RXR have two zinc fingers [22, 24], zinc deficiency could
impair the function of this transcription factor complex and thus lead to inflammation.
The present study utilized the porcine vascular endothelial cell model to further
investigate the effects of zinc deficiency on endothelial cell dysfunction with a focus on
NF-κB and PPAR pathways. In order to demonstrate the requirement of zinc for PPAR
transactivation function, transient transfection-luciferase assays were performed in rat
aortic vascular smooth muscle cells. We hypothesize that zinc deficiency, by activating
NF-κB and inhibiting PPAR signaling, induces endothelial cell activation.

2.3

Materials and Methods

Cell culture and experimental media
Endothelial cells were isolated from porcine pulmonary arteries and subcultured
in Medium 199 (M-199) (Invitrogen Corporation, Carlsbad, CA) containing 10% (v/v)
fetal bovine serum (FBS) (HyClone, Logan, UT) as previously described [75, 76]. The
experimental media were composed of M-199 enriched with 1 % (v/v) FBS. Zinc (20
µM) was added as zinc acetate from a stock solution in water. N, N, N', N'-Tetrakis (2pyridylmethyl) ethylene diamine (TPEN, 1.5 or 1.0 µM) was added from a stock solution
in ethanol. Caffeic acid phenethyl ester (CAPE, 1.0 μg/mL) and rosiglitazone (RSG, 10
µM) were added from stock solutions in DMSO. When 90 % confluent, the cells were
synchronized with M-199 containing 0 % (v/v) FBS overnight and then treated with zinc
and/or TPEN and/or CAPE and/or rosiglitazone for 24 h.
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Measurement of cellular oxidative stress
Oxidative stress was measured as previously described [77] with minor
modifications. Endothelial cells in 24-well plate were treated with vehicle control
(ethanol, 0.05 %), TPEN (1.0 μM), TPEN (1.0 μM) plus Zn (20 μM), or Zn (20 μM)
alone for 24 h, and washed twice with HEPES buffered salt solution (HBSS, pH 7.4)
containing 25 mM HEPES, 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 25 mM
NaHCO3, and 15 mM glucose. After an incubation with 10 μM of 2’,7’dichlorodihydrofluorescein diacetate (H2DCF-DA) for 30 minutes at 37°C in the dark,
cells were washed twice with HBSS and replaced with 1 ml of HBSS. DCF fluorescence
(relative fluorescence intensity) was measured using a SpectraMax® M2 microplate
reader (Molecular Devices Corporation, Sunnyvale, CA) with excitation and emission
wavelengths of 485 nm and 530 nm, respectively.

Measurement of PPARα, cyclooxygenase-2 (COX-2) and endothelial cell selectin (Eselectin) gene expression
Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s directions. cDNA was generated using the Reverse
Transcription System (Promega, Madison, WI). Gene expression of PPARα was
determined by real-time PCR (RT-PCR) using the ABI Prism 7300 Real Time PCR
System (Applied Biosystems, Branchburg, NJ) and SYBR® GREEN PCR Master Mix
(Applied Biosystems, Branchburg, NJ). The primers used were: PPARα, forward, 5’CAT GCC TGT GAA GGT TGC AA -3’, and reverse, 5’- CAG CTC CGA TCA CAT
TTG TCA T -3’; β-actin, forward, 5’- TCA TCA CCA TCG GCA ACG -3’, and
reverse, 5’-TTC CTG ATG TCC ACG TCG C -3’. Gene expression of COX-2 and Eselectin was determined by RT-PCR. Specific primer sequences were synthesized by
IDT Technologies, Inc, San Jose, CA. The primers used were: COX-2, forward, 5'GGA GAG ACA GCA TAA ACT GC -3', and reverse, 5'- GTG TGT TAA ACT CAG
CAG CA -3’; E-selectin, forward, 5’-GAC TCG GGC AAG TGG AAT GAT GAG -3’,
and reverse, 5’- CAT CAC CAT TCT GAG GAT GGC GGA C -3’; β-actin, forward, 5’GGG ACC TGA CCG ACT ACC TC-3’, and reverse, 5’-GGG CGA TGA TCT TGA
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TCT TC-3’. β-actin was used as an endogenous control for normalizing the expression of
genes of interest.

Measurement of PPARα and COX-2 protein expression
Cellular protein was extracted as previously described [62]. Cellular protein
extracts (25 μg) were electrophoresed on 8-10% SDS-polyacrylamide gels followed by
transfer to nitrocellulose membranes (Bio-Rad Laboratories, Hercules, CA). The
membranes were incubated in blocking buffer [5% nonfat milk in tris-buffered saline (pH
7.6) containing 0.05 % tween 20 (TBST)] for 1 hour followed by incubation with a
1:1000 dilution of PPARα rabbit polyclonal IgG (Cayman Chemical Company, Ann
Arbor, MI) or COX-2 goat polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, CA)
or a 1:4000 dilution of β-actin rabbit polyclonal antibody (Sigma, St. Louis, MO) in
blocking buffer overnight at 4°C. β-actin was used as an endogenous control to
normalize the expression of proteins of interest. The membranes were then incubated
with a goat anti-rabbit (Cell Signaling Technology, Inc., Danvers, MA) or mouse antigoat (Santa Cruz Biotechnology, Santa Cruz, CA) secondary antibody conjugated to
horseradish peroxidase. Signals of the blots were measured using the enhanced
chemiluminescence (ECL) detection system (GE Healthcare, Piscataway, NJ).

Monocyte Adhesion Assay
The monocyte adhesion assay was performed with modifications as described
previously [77]. Endothelial cells were treated with vehicle control (ethanol, 0.05 % and
DMSO, 0.1 %), TPEN (1.0 μM), TPEN (1.0 μM) plus zinc (20 μM), zinc (20 μM) alone,
rosiglitazone (10 μM) alone, rosiglitazone (10 μM) plus TPEN (1.0 μM), rosiglitazone
(10 μM) plus TPEN (1.0 μM) and zinc (20 μM), or rosiglitazone (10 μM) plus zinc (20
μM) for 24 h in 6-well plates. Human THP-1 monocytes (50,000 cells/well) were
activated with 10 ng/mL of TNFα for 10 min, then labeled with 3 μg/mL of the
fluorescent probe calcein (Molecular Probes, Carlsbad, CA) by incubation at 37 °C for 15
min. After two times of washing with 1 % FBS/M199, THP-1 monocytes were
resuspended in 1% FBS/M199, added to the treated endothelial cell monolayers (50 μL/
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well) and incubated at 37 °C for 30 min to allow for monocyte adhesion. Nonadherent
monocytes were washed away with 1% FBS/M199, and the monolayers were fixed with
500 μL/well of 1% glutaraldehyde at room temperature for 30 minutes. Attached
fluorescent monocytes were counted using an Olympus IX70-S1F2 microscope
(Olympus Optical Co., Ltd., Japan). The monocyte adhesion assays were performed by
Elizabeth Oesterling at the University of Kentucky Molecular and Cell Nutrition
Laboratory (Hennig’s laboratory).

Transcription factor (NF-κB and PPAR): DNA interaction studies: electrophoretic
mobility shift assay (EMSA)
Endothelial cells were treated with vehicle control (ethanol, 0.05 %), TPEN (1.0
μM), TPEN (1.0 μM) plus Zn (20 μM), or Zn (20 μM) alone for 24 h. Nuclear proteins
were extracted as previously described [78]. EMSA assays were performed using
LightShift® Chemiluminescent EMSA Kit (PIERCE, Rockford, IL). Nuclear extracts
were incubated for 25 min at room temperature with 5’-biotin-labeled oligonucleotide
probes containing the specific DNA binding consensus sequences for NF-κB (Promega,
Madison, WI) or PPAR (Santa Cruz, Santa Cruz, CA). Incubation was performed in the
presence of nonspecific competitor DNA (Poly dI-dC). Following binding, the
transcription factor complexed DNA and free probe in the mixture were resolved by
electrophoresis in a 6.0 % (w/v) non-denaturing polyacrylamide gel followed by transfer
to nylon membranes (Thermo Scientific, Rockford, IL), and visualized by
autoradiography. Control reactions using supershift assay were performed to demonstrate
the specificity of the shifted DNA-protein complexes for NF-κB and PPAR, respectively.
Antibodies for NF-κB p65 and PPARα were obtained from Santa Cruz (Santa Cruz
Biotechnology, Santa Cruz, CA) and Cayman (Cayman Chemical Company, Ann Arbor,
MI), respectively.

Transient transfection and luciferase assay
Rat aortic vascular smooth muscle cells (RAVSMC) were grown in 6-well plates
in DMEM (Invitrogen Corporation, Carlsbad, CA) containing 10 % FBS (Invitrogen
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Corporation, Carlsbad, CA). Media were changed to DMEM containing 2 % FBS
without antibiotics, in which the cells were treated with 600 nM of the zinc chelator

diethylenetriaminepentaacetic acid (DTPA) (Sigma-Aldrich, Saint Louis, MO) with or
without 600 nM ZnSO4 for 24 h. Subsequently, 400 ng DNA of the acyl-CoA oxidase
PPRE-Tk-luciferase reporter construct and 200 ng of the full-length PPARγ1 expression
vector were co-transfected using Lipofectamine 2000 (Invitrogen Corporation, Carlsbad,
CA) and OPTI-MEM®I (Invitrogen Corporation, Carlsbad, CA) [79]. After transfection
for 6-8 h, cells were stimulated with 10 μmol/L of rosiglitazone for 24 h. Luciferase
activity was measured using a Dual-Luciferase Reporter Assay System (Promega,
Madison, MA) according to the manufacturer's instructions. Transfection efficiency was
adjusted by normalizing firefly luciferase activities to the renilla luciferase activities
generated by co-transfection with 10 ng pGL4.74 [hRluc/TK] (Promega, Madison, MA).

Statistical analysis
Statistical analysis was performed with SPSS 12.0 (SPSS, Inc., Chicago, IL).
Data were analyzed using one way ANOVA with post hoc comparisons of the means by
least significance difference (LSD) procedure. Differences were considered significant at
P < 0.05. Data are means ± standard error of the mean (SEM).

2.4

Results

Zinc deficiency increases cellular oxidative stress in vascular endothelial cells
Zinc deficiency caused by TPEN markedly increased cellular oxidative stress (P <
0.05, Fig. 2.1), which was reduced by zinc supplementation to the chelator-containing
media (P < 0.05, Fig. 2.1). Zinc supplementation alone caused a similar level of cellular
oxidative stress to that in zinc supplemented TPEN treated cells (Fig. 2.1).

Zinc deficiency increases NF-κB DNA binding activity in vascular endothelial cells
Similar results were observed with NF-κB DNA binding activity (Fig. 2.2), which
was markedly increased during zinc deficiency (P < 0.01, Fig. 2.2) and significantly
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reduced during zinc supplementation (P < 0.01, Fig. 2.2). Zinc supplementation alone
did not affect NF-κB DNA binding activity (Fig. 2.2).

Zinc deficiency induces gene expression of COX-2 and E-selectin in vascular
endothelial cells
To test the effect of zinc deficiency on pro-inflammatory genes down-stream of
NF-κB, gene expression of COX-2 and E-selectin was assessed by RT-PCR analysis.
Both COX-2 (Fig. 2.3A) and E-selectin (Fig. 2.3B) mRNAs were markedly up-regulated
during zinc deficiency and restored to control levels following zinc supplementation (Fig.
2.3). Zinc supplementation alone had no effect on the expression of either COX-2 or Eselectin mRNA (Fig. 2.3).

Inhibition of NF-κB reduces the up-regulation of COX-2 protein by zinc deficiency in
vascular endothelial cells
Consistent with the COX-2 gene expression data, TPEN-induced zinc deficiency
led to a significant increase in COX-2 protein level in endothelial cells (P < 0.001, Fig.
2.4). CAPE, a specific NF-κB inhibitor, at the concentration of 1.0 μg/mL, did not have
any effect on COX-2 protein expression. However, when cells were co-treated with
TPEN and CAPE, the induction of COX-2 by TPEN was partially blocked (P < 0.001,
Fig. 2.4), suggesting that NF-κB activation is involved in the induction of COX-2 protein
by TPEN.

Zinc deficiency decreases PPARα mRNA and protein expression in vascular
endothelial cells
Zinc deficiency greatly decreased PPARα mRNA expression in vascular
endothelial cells (P < 0.05, Fig. 2.5A), which was partially restored by zinc
supplementation to TPEN-containing media (P < 0.05, Fig. 2.5A). Zinc supplementation
alone caused a similar level of PPARα mRNA expression to that in zinc supplemented
TPEN treated cells (Fig. 2.5A). Similar results were obtained with PPARα protein
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expression, which was also decreased by zinc chelation and restored by zinc
supplementation (P < 0.05, Fig. 2.5B).

Zinc deficiency decreases PPAR DNA binding activity in vascular endothelial cells
Zinc deficiency significantly decreased PPAR DNA binding activity in vascular
endothelial cells (P < 0.05, Fig. 2.6). Zinc supplementation tended to restore the PPAR
DNA binding activity to the control level (Fig. 2.6).

Zinc deficiency increases monocyte adhesion to vascular endothelial cells and blocks
the inhibitory effect of rosiglitazone on monocyte adhesion
Zinc deficiency significantly increased monocyte adhesion to vascular endothelial
cells (P < 0.001, Fig. 2.7). Zinc supplementation ameliorated the monocyte adhesion
observed during zinc deficiency. Rosiglitazone was unable to block adhesion of
monocytes to endothelial cells during zinc deficiency (P < 0.001); however, inhibition of
monocyte adhesion by rosiglitazone was observed following zinc supplementation (Fig.
2.7).

Adequate zinc is required for functional activity of PPARγ
PPARγ transactivation activity in PPARγ and PPRE co-transfected RAVSMC
was induced by rosiglitazone in zinc adequate cells (P < 0.001, Fig. 2.8). Zinc deficiency
caused by DPTA inhibited PPARγ transactivation activity induced by rosiglitazone (P <
0.05, Fig. 2.8), which could be reversed by zinc supplementation (P < 0.05, Fig. 2.8).

2.5

Discussion
Evidence indicates that major chronic or age-related diseases, such as

atherosclerosis, arthritis, dementia, osteoporosis, and cardiovascular diseases, are
inflammation-related, and that a balance between NF-κB and PPAR signaling is a critical
regulator of inflammation-related diseases [80]. Furthermore, zinc deficiency or a
disturbance in zinc homeostasis in individuals genetically predisposed to a dysregulation
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of the inflammatory and/or immune response may contribute to adverse effects associated
with age-related diseases [81]. Zinc plays an important role in reactions related to cellmediated immunology and also functions as an antioxidant and anti-inflammatory
nutrient [82]. The results from the studies described above suggest that zinc deficiency
activates vascular endothelial cells through activation of NF-κB and inhibition of PPAR
pathways.
NF-κB is well known to be a key signaling pathway to up-regulate adhesion
molecules [3], but the effect of endothelial cellular zinc status on adhesion molecule and
other NF-κB regulated gene expression has rarely been reported. The anti-inflammatory
and anti-atherogenic roles of PPAR in endothelial cells have aroused interest only in
recent years with the findings that adequate zinc is required for proper PPAR signaling
in these cells [25, 26].
The present study looked at the influence of endothelial zinc status on adhesion
molecule and other NF-κB regulated gene expression and further investigated the
molecular mechanisms involved in zinc deficiency-induced endothelial cell activation.
Oxidative stress is believed to play a fundamental role in the etiology of cardiovascular
diseases, including atherosclerosis [83, 84]. The finding that zinc deficiency induced by
TPEN chelation increased cellular oxidative stress is consistent with our previous finding
that zinc deficiency induced by endothelial cell culture in low serum media for eight days
can cause an increase in oxidative stress [10]. NF-κB is an oxidative stress sensitive
transcription factor and critical in the regulation of an inflammatory response [85].
Furthermore, activated NF-κB has been found in human atherosclerotic plaques [86],
suggesting its importance in the etiology of atherosclerosis. In the current study, zinc
deficiency significantly increased NF-κB DNA binding activity. However, our previous
studies using long term (8-10 day) culture of endothelial cells in low serum (zincdeficient) media have shown that zinc deficiency by itself, without additional oxidative
stress, does not increase [87] or only slightly increases NF-κB DNA binding [10]. The
different observations of the effect of zinc deficiency on NF-κB DNA binding may be
due to the different ways of making endothelial cells zinc-deficient, and possibly the
extent of zinc deficiency as well. Both COX-2 and E-selectin are NF-κB regulated genes
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[88, 89]. COX-2 catalyzes production of the pro-inflammatory prostaglandin E2 (PGE2)
and is highly induced and active at sites of inflammation [90]. E-selectin is an adhesion
molecule expressed on the surface of activated vascular endothelial cells that mediates
adhesion of neutrophils, monocytes, and memory T-cells to endothelial cells [89, 91]. In
the current study, as a consequence of zinc deficiency-induced NF-κB activation, both
COX-2 and E-selectin genes were significantly up-regulated, with the latter contributing
to the observed increased adhesion of THP-1 monocytes to the activated endothelial cells.
CAPE is a potent and specific inhibitor of NF-κB activation that acts by preventing the
translocation of p65 subunit of NF-κB to the nucleus, thus inhibiting NF-κB DNA
binding [92]. In our study, COX-2 protein expression induced during zinc deficiency
was partially blocked by CAPE, again suggesting that NF-κB activation is involved in the
up-regulation of inflammatory markers by zinc deficiency in vascular endothelial cells.
PPARs, and especially PPARα and PPARγ, are inhibitors of NF-κB [21];
therefore dysfunctional PPAR signaling will lead to activation of NF-κB. PPARα can
repress the NF-κB pathway via interactions with the p65 subunit of NF-κB [34].
Similarly, PPARγ can inhibit the NF-κB pathway by physically interacting with p50 and
p65 subunits of NF-κB [35]. PPARα agonists, such as fibrates, induce IκBα (an
inhibitor of NF-κB) expression, providing an additional mechanism for the inhibition of
NF-κB by PPARα [36]. In the present study, PPARα expression at both the mRNA and
protein levels was decreased due to zinc deficiency and this effect was reversible by zinc
supplementation. Similar effects of zinc deficiency and zinc supplementation were
observed on PPARγ expression in vascular endothelial cells [25]. Furthermore, our
previous study has shown that both PPARα and PPARγ agonists can induce PPAR DNA
binding activity, which was compromised during zinc deficiency [26]. In this study, zinc
deficiency consistently decreased PPAR DNA binding activity in endothelial cells. The
present transfection-luciferase assay demonstrated that zinc deficiency can inhibit
rosiglitazone-induced PPARγ transactivation activity and that this effect can also be
reversed by zinc supplementation. As expected, compromised PPARγ function was
observed in the current study during zinc deficiency. This was reflected by the
requirement of adequate zinc for rosiglitazone to inhibit monocyte-endothelial cell
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adhesion. Taken together, these findings clearly demonstrate that zinc deficiency
compromises PPAR function.
In conclusion, our present in vitro studies suggest that zinc deficiency intensifies
pro-inflammatory and impairs anti-inflammatory responses in vascular endothelial cells
though activation of NF-κB and inhibition of PPAR pathways. Zinc adequacy therefore
has important implications in preventing endothelial cell dysfunction and subsequent
cardiovascular diseases such as atherosclerosis.

24

10
a

Oxidative Stress

8

b
b

6

4
c
2

0
Control

TPEN

TPEN + Zn

Zn

Figure 2.1. Zinc deficiency increases cellular oxidative stress in endothelial cells.
Endothelial cells were exposed to vehicle control (ethanol, 0.05 %), TPEN (1.0 μM),
TPEN (1.0 μM) plus Zn (20 μM), or Zn (20 μM) for 24 h. Oxidative stress was measured
by DCF fluorescence (relative fluorescence units). Values are means ± SEM, n = 4-6.
Means without a common letter differ (a > b > c), P < 0.05.
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Figure 2.2. Zinc deficiency increases NF-κB DNA binding activity in endothelial
cells.
Endothelial cells were exposed to vehicle control (ethanol, 0.05 %), TPEN (1.0 μM),
TPEN (1.0 μM) plus Zn (20 μM), or Zn (20 μM) for 24 h. The vertical axis represents
densitometric units. Values are means ± SEM, n = 3. Means without a common letter
differ (a > b), P < 0.01. The gel data are a representative of the typical outcome of three
repeated EMSA experiments.
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Figure 2.3. Zn deficiency induces COX-2 (A) and E-selectin (B) mRNA expression in
endothelial cells.
A. COX-2 mRNA expression measured by RT-PCR. B. E-selectin mRNA expression
measured by RT-PCR. Endothelial cells were exposed to vehicle control (ethanol, 0.075
%), TPEN (1.5 μM), TPEN (1.5 μM) plus Zn (20 μM), or Zn (20 μM) for 24 h. The
vertical axes represent ratios of the densitometric units of COX-2 or E-selectin mRNA
over those of β-actin mRNA, respectively, expressed as percentage of control. Values are
means ± SEM, n = 4. Means without a common letter differ (a > b), P < 0.01(A) or 0.05
(B). The gel data are a representative of the typical outcome of four repeated RT-PCR
experiments.
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Figure 2.4. Zinc deficiency-induced COX-2 protein expression in endothelial cells is
partially reduced during inhibition of NF-κB activation.
Endothelial cells were exposed to vehicle control (ethanol, 0.05 % and DMSO, 0.04 %),
TPEN (1.0 μM), CAPE (1.0 μg/mL), or TPEN (1.0 μM) plus CAPE (1.0 μg/mL) for 24 h.
The values are ratios of the densitometric units of COX-2 over those of β-actin. Values
are means ± SEM, n = 3. Means without a common letter differ (a > b > c), P < 0.001.
The gel data are a representative of the typical outcome of three repeated Western Blot
experiments.
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Figure 2.5. Zn deficiency decreases PPARα expression in endothelial cells.
Endothelial cells were exposed to vehicle control (ethanol, 0.075 %), TPEN (1.5 μM),
TPEN (1.5 μM) plus Zn (20 μM), or Zn (20 μM) for 24 h. A. PPARα mRNA expression
measured by real-time PCR. The vertical axis represents relative units, calculated as the
ratio of the copy number of PPARα over the copy number of β-actin, the endogenous
control. Values are means ± SEM, n = 4. Means without a common letter differ (a > b >
c), P < 0.05. B. PPARα protein expression measured by Western blot. The values are
ratios of the densitometric units of PPARα over those of β-actin, expressed as percentage
of control. Values are means ± SEM, n = 4. Means without a common letter differ (a >
b), P < 0.05. The gel data are a representative of the typical outcome of four repeated
Western Blot experiments.
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Figure 2.6. Zn deficiency decreases PPAR DNA binding activity in endothelial cells.
Endothelial cells were exposed to vehicle control (ethanol, 0.05 %), TPEN (1.0 μM),
TPEN (1.0 μM) plus Zn (20 μM), or Zn (20 μM) for 24 h. Values are means ± SEM, n =
3. Means without a common letter differ (a > b), P < 0.05. The gel data are a
representative of the typical outcome of three repeated EMSA experiments.
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Figure 2.7. Zinc deficiency increases monocyte adhesion to endothelial cells and
blocks the inhibitory effect of rosiglitazone on monocyte adhesion.
Endothelial cells were exposed to vehicle control (ethanol, 0.05 % and DMSO, 0.1 %),
TPEN (1.0 μM), TPEN (1.0 μM) plus Zn (20 μM), Zn (20 μM), rosiglitazone (RSG, 10
μM), RSG (10 μM) plus TPEN (1.0 μM), RSG (10 μM) plus TPEN (1.0 μM) and Zn (20
μM), or RSG (10 μM) plus Zn (20 μM) for 24 h followed by incubation with human
THP-1 monocytes for 30 min. Monocyte adhesion is expressed as numbers of monocyte
adhered per microscopic high power field, with 5 ~ 7 fields examined per well. Values
are means ± SEM, n = 3. Means without a common letter differ (a > b), P < 0.01.
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Figure 2.8. Effect of zinc status on rosiglitazone-induced PPARγ transactivation in
PPARγ and PPRE co-transfected RAVSMC.
PPARγ transactivation activity was measured as relative luciferase activity (firefly
luciferase activity: renilla luciferase activity). Means without a common letter differ (a >
b > c), P < 0.05. Values are means ± SEM, n = 3. The results represent the outcome of
three repeated experiments.
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Chaper 3. Zinc Deficiency Alters Pro-inflammatory and Anti-inflammatory
Responses in LDL-Receptor-Deficient Mice Treated with Rosiglitazone
3.1

Synopsis
Marginal intake of dietary zinc can be associated with increased risk of

cardiovascular diseases. Zinc has potent antioxidant and anti-inflammatory properties.
Zinc is also a structural and functional component of PPAR. Numerous studies indicate
that rosiglitazone, a selective and potent PPARγ agonist, has antioxidant and antiinflammatory effects and would be beneficial in inflammatory conditions, such as
atherosclerosis. The present study focused on the hypothesis that PPARγ signaling, and
especially its anti-inflammatory properties, are dysfunctional during zinc-deficiency and
that adequate dietary zinc is critical for anti-inflammatory properties of PPARγ agonists
such as rosiglitazone. LDL-R deficient (LDL-R-/-) mice were maintained for three weeks
on low-fat (7g/100g) diets that were either zinc deficient or zinc adequate. Subsequently,
the low-fat regimen was switched to a high-fat (15g/100g) regimen for one week to
induce a biological environment of mild oxidative and inflammatory stress. Half of the
mice within each zinc group were gavaged with rosiglitazone two days prior to the high
fat feeding. Subsequently, expression of selected pro-inflammatory genes was measured
in abdominal aorta. IκBα protein expression and DNA binding activities of NF-κB and
PPAR in liver were also assayed. Furthermore, concentrations of pro- and antiinflammatory cytokines/chemokines were determined in plasma. Rosiglitazone induced
inflammatory genes (e.g., MCP-1) only during zinc deficiency, and adequate zinc was
required for rosiglitazone to down-regulate pro-inflammatory markers such as iNOS. In
addition, rosiglitazone increased IκBα protein expression only in zinc adequate mice.
Finally, plasma cytokine profiles suggest an overall pro-inflammatory environment
during zinc deficiency and support the concept that zinc is required for proper antiinflammatory or protective functions of PPAR. These data suggest that in this
atherosclerotic mouse model the proper anti-inflammatory function of PPARγ was
compromised during zinc deficiency and that adequate dietary zinc is critical for antiinflammatory properties of the PPARγ agonist rosiglitazone.
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3.2

Introduction
Atherosclerosis and its complications are the main causes of morbidity and

mortality of coronary heart disease [2, 93]. Atherosclerosis is a chronic inflammatory
disease that may progress over many decades and is characterized by the accumulation of
lipids and fibrous elements in large arteries [2]. Atherosclerotic lesions are thought to be
initiated by vascular endothelial cell dysfunction followed by monocyte adhesion,
invasion and macrophage foam cell formation [1, 94]. Interaction between modified
lipoproteins, macrophage foam cells, T cells, and the normal cellular elements of the
arterial wall, such as smooth muscle cells [94], results in the formation and progression of
atherosclerotic lesions [1]. In addition to genetic risk factors, such as high LDL and
VLDL levels and low HDL levels, the development of atherosclerosis is greatly
influenced by lifestyle as well as nutritional factors, such as zinc deficiency [1-3], which
has been suggested to be associated with coronary artery disease by epidemiological
studies [67]. Several molecular and cellular mechanisms on how zinc deficiency could
contribute to the pathogenesis of atherosclerosis have been found. For example, zinc
deficiency can enhance oxidative stress-related signaling in endothelial cells, including
activation of NF-κB, which is a key transcription factor leading to adhesion molecule upregulation and inflammatory response, induction of caspase-mediated apoptosis of
endothelial cells, which is also a characteristic of atherosclerosis, and changes in NO
signaling, which is linked to the development of atherosclerosis [3]. The anti-atherogenic
properties of zinc with a focus on endothelial cell metabolism have been previously
reviewed [95].
Zinc is an essential trace element required in biological systems for many
physiological functions. Zinc is recognized as a growth factor, membrane and
cytoskeleton stabilizer, anti-inflammatory and antioxidant agent, and anti-apoptotic agent
[4, 28, 70]. Zinc is a structural component of numerous zinc-finger proteins and plays
functional roles in these proteins [4, 11]. PPAR is a ligand-activated transcription factor
which has anti-inflammatory properties by interfering with major inflammatory pathways
such as NF-κB and AP-1, and inhibiting inflammatory responses with decreased
inflammatory cytokine and deactivated inflammatory mediators [21]. Since the DNA
binding domains of PPAR and its DNA binding partner RXR both have two zinc fingers
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[22, 24], zinc deficiency may affect proper function of the PPAR:RXR transcription
factor complex and compromise the anti-inflammatory properties of PPAR.
The synthetic PPARγ agonist, rosiglitazone, one member of thiazolidinediones
(TZDs), is clinically used to treat type II diabetes [96]. In addition to its insulinsensitizing anti-diabetic effects [96], rosiglitazone has potent anti-inflammatory and antiatherosclerotic properties [97, 98] and is able to inhibit the development of
atherosclerosis in LDL-R-/- [99] and apolipoprotein E deficient (ApoE-/-) mice [100].
Rosiglitazone has also been shown to attenuate vascular inflammation in both type II
diabetic [101] and non-diabetic patients [102, 103]. Substantial experimental and clinical
studies have provided evidence that chronic administration of TZDs, including
rosiglitazone, is beneficial on cardiovascular system [38].
Some in vitro studies using porcine vascular endothelial cells have shown that
zinc can modulate PPAR function [25] and that adequate zinc is important for antiinflammatory properties of PPARα and γ [26]. The next question is whether the
requirement of zinc for PPAR to exert its anti-inflammatory effect is also the case in vivo.
To answer this question we carried out the current animal study utilizing an atherogenic
mouse model (LDL-R-/- mice). We hypothesize that rosiglitazone, by activating PPARγ,
is able to decrease high-fat diet induced inflammatory responses in LDL-R-/- mice, and
that this protective effect of rosiglitazone is dependent on adequate zinc intake.

3.3

Materials and Methods

Animals and diets
The atherosclerosis-prone animal model used in this study was the homozygous
LDL-R null strain of mouse with a C57BL6/J Background. These mice develop marked
hypercholesterolemia and early to intermediate atherosclerotic lesions after 6 to 8 weeks
on a high-fat, high-cholesterol diet [104]. The mice were obtained from The Jackson
Laboratory (Bar Harbor, ME; Stock Number: 002207) and housed 4 per cage in plastic
cages with wire mesh floors over wood chip bedding. Cellulose pads were provided to
the mice for nesting and a 12 h light/dark cycle was maintained. Mice were given ad
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libitum access to distilled water provided through plastic bottles with plastic stoppers to
reduce zinc contamination. All procedures were in compliance with and approved by the
Iowa State University Animal Care and Use Committee. LDL-R-/- mice were obtained at
5 wk of age, weighed 16.3 g on average, and were fed a low-fat (LF) diet with either 0.4
mg/kg of zinc (0 Zn, zinc-deficient diet) or 33.1 mg/kg of zinc (30 Zn, zinc-adequate
diet). After 21 d of feeding the LF diet, all mice were assigned to a high-fat (HF) diet,
without changing the original zinc nutritional status. Mice were fed the HF diet for one
week. Diets were prepared based on AIN-93 standards [105] but used egg white rather
than casein as the protein source in order to provide a low zinc diet [106] (Table 3.1). The
diets were of similar caloric value, 18.17 kJ/g for the HF and 16.50 kJ/g for the LF diets,
respectively. Rosiglitazone (RSG, 20 mg ∙ kg-1 ∙ d-1) [99] or the vehicle (0.25% of
methylcellulose) were administered for 9 d by oral gavage. RSG treatment was initiated
2 d prior to the start of the HF dietary regimen. Body weights of all mice were
determined every 2 d throughout the study. After completion of the study (4 wk), the
mice were euthanized by intraperitoneal phenobarbital injection (Fig. 3.1).
Food intake was measured over a 3 day period within the first week of the study.
Mean food intake was not statistically different in zinc deficient vs. zinc adequate mice at
this time. In a preliminary study we observed that mice fed the zinc-deficient diet cycle
their food intake between 100 % and 75 % of that of the zinc-adequate animals during
this time period with a net overall decrease of about 16% of food intake in zinc-deficient
mice.

Zinc quantification
Blood was drawn from exposed hearts using heparinized syringes. Plasma
samples were prepared by centrifugation at 14,000 × g at room temperature for 10 min.
Livers were flash frozen in liquid nitrogen after excision. Both plasma and liver samples
were stored at -80° C prior to analysis. Zinc concentrations in plasma, liver and RSG
solution were analyzed by inductively coupled plasma (ICP) mass spectrometry by Dr.
Thomas Mawhinney at the University of Missouri-Columbia Agricultural Experiment
Station Chemical Laboratory (Columbia, MO) [107].
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Measurement of plasma cytokines and chemokines
Concentrations of plasma IL-1α, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17,
TNFα, and MCP-1 were measured using Mouse Cytokine/Chemokine LINCOplex kit
(LINKO Research Inc., St. Louis, MO). Luminex 100 (Luminex Corporation, Austin,
TX) and Multiplex Data Analysis Software 1.0 (Upstate USA, Inc., Chicago, IL) were
utilized for signal detection and data analysis, respectively, by Jason Stevens at the
University of Kentucky Center for Oral Health Research.

Gene expression analysis
Abdominal aortas were excised from the mice, immerged in RNAlater (Qiagen,
Valencia, CA) and stored at -80° C until analysis. Total RNA was isolated from
abdominal aorta using RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA) after
surrounding adipose and connective tissues were removed. cDNA was generated using
the Reverse Transcription System (Promega, Madison, WI). Gene expression was
determined by real-time PCR using the ABI Prism 7300 Real Time PCR System
(Applied Biosystems, Branchburg, NJ) and TaqMan® Universal PCR Master Mix, No
AmpErase® UNG (Applied Biosystems, Branchburg, NJ). TaqMan® gene expression
assays were used for mouse iNOS and MCP-1 (Applied Biosystems, Branchburg, NJ).
Each assay consisted of a specific pair of unlabeled PCR primers and a specific
TaqMan® MGB probe that was 5’ end labeled with a FAMTM reporter dye and 3’ end
labeled with a minor groove binder/non-fluorescent quencher (MGBNFQ). Detection of
18S rRNA, or β-actin as endogenous control, utilized pre-developed Taqman assay
reagents, i.e. Eukaryotic 18S rRNA Endogenous Control or Mouse ACTB Endogenous
Control (Applied Biosystems, Branchburg, NJ).

Measurement of IκBα protein expression
Liver tissues were flash frozen and stored at -80 °C until analysis. Frozen tissue
was cut on ice into approximately 2 mm3 pieces with scalpel and submerged into ice cold
lysis buffer containing 50 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2 mM
DTT, 1 mM Na3VO4, 0.1 mg/mL phenylmethanesulfonyl fluoride (PMSF), 2.5 μg/mL
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leupeptin, 10 μg/mL pepstatin A, 10 μg/mL aprotinin, 0.5 % nonidet P-40, and 0.5 %
Triton X-100. The liver tissue was homogenized on ice for 10 min and the homogenate
was kept on ice for another 30 min followed by centrifugation at 14,000 rpm at 4 °C for
30 min. Cellular protein extract was obtained by collecting the supernatant. 25 μg of
cellular protein extracts were electrophoresed on 8 % SDS-polyacrylamide gels followed
by transfer to nitrocellulose membranes. The membranes were blocked with blocking
buffer [5% nonfat milk in tris-buffered saline (pH 7.6) containing 0.05 % tween 20
(TBST)] for 1 h followed by incubation with a 1:1000 dilution of rabbit anti-IκBα, Cterminal polyclonal antibody (Millipore, Billerica, MA) or a 1:4000 dilution of rabbit
anti-actin polyclonal antibody (Sigma, St. Louis, MO) in blocking buffer overnight at
4°C. β-actin was used as an endogenous control to normalize the expression of IκBα.
The membranes were then incubated with a goat anti-rabbit secondary antibody
conjugated to horseradish peroxidase (Cell Signaling Technology, Inc., Danvers, MA).
Signals of the blots were measured using the enhanced chemiluminescence (ECL)
detection system (GE Healthcare, Piscataway, NJ).

Transcription factor (NF-κB and PPAR):DNA interaction studies: electrophoretic
mobility shift assay (EMSA)
Liver tissues were flash frozen and stored at -80 °C until analysis. Nuclear
proteins were extracted using CelLyticTM NuCLEARTM Extraction Kit (Sigma-Aldrich,
St. Louis, MO) according to the manufacturer’s instruction. EMSA assays were
performed using LightShift® Chemiluminescent EMSA Kit (PIERCE, Rockford, IL).
Nuclear extracts were incubated for 25 min at room temperature with 5’-biotin-labeled
oligonucleotide probes containing the specific DNA binding consensus sequences for
NF-κB (Promega, Madison, WI) or PPAR (Santa Cruz, Santa Cruz, CA). Incubation was
performed in the presence of nonspecific competitor DNA (Poly dI-dC). Following
binding, the transcription factor complexed DNA and free probe in the mixture were
separated by electrophoresis in a 6.0 % (w/v) non-denaturing polyacrylamide gel
followed by transfer to nylon membranes (Thermo Scientific, Rockford, IL), and
visualized by autoradiography. Control reactions using supershift assay were performed
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to demonstrate the specificity of the shifted DNA-protein complexes for NF-κB and
PPAR, respectively. Antibodies for NF-κB p65 and PPARα were obtained from Santa
Cruz (Santa Cruz Biotechnology, Santa Cruz, CA) and Cayman (Cayman Chemical
Company, Ann Arbor, MI), respectively.

Statistical analyses
Data were expressed as means ± SEM and analyzed using SPSS 12.0 (SPSS, Inc.,
Chicago, IL) and JMP 7.0 (SAS, Inc., Cary, NC). Zinc and RSG were used as
explanatory variables in two-way ANOVA models. Non significant interactions were
removed from the models. Post hoc comparisons were conducted using LSD method
only when there were significant interactions in the two-way model. A statistical
probability of P < 0.05 was considered significant. Actual P values were reported when
less than 0.1.

3.4

Results
Body weight was unchanged until day 9, but subsequently only increased in zinc-

adequate mice (Fig. 3.2). Rosiglitazone treatment had no effect on body weight within
either zinc adequate or deficient groups, respectively (Fig. 3.2). Body weights in each
group at the end of the feeding study were (mean ± SEM): 0 Zn, 16.43 ± 1.20 g; 0 Zn +
RSG, 15.12 ± 0.52 g; 30 Zn, 19.56 ± 0.26 g; 30 Zn + RSG, 19.29 ± 0.48 g.
Plasma zinc concentrations were not different in the LDL-R-/- mice fed the zincdeficient diet compared to the zinc-adequate diet regardless of rosiglitazone treatment
(Fig. 3.3). Treatment with rosiglitazone resulted in increased plasma zinc concentrations
in both dietary groups (P < 0.001, Fig. 3.3). Liver zinc concentration was lower in
untreated mice fed the zinc-deficient diet compared to the zinc-adequate diet (P < 0.001,
Fig. 3.3). In mice fed the zinc-adequate diet only, rosiglitazone treatment resulted in
reduced liver zinc concentration (P < 0.01, Fig. 3.3).
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The effects of rosiglitazone on expression of pro-inflammatory genes in LDL-R-/- mice
are regulated by zinc status
Rosiglitazone treatment resulted in lower levels of iNOS mRNA expression in
abdominal aortas compared with untreated mice (P < 0.01, Fig. 3.4A). The zinc adequate
untreated mice had a higher level of iNOS mRNA expression in abdominal aorta than the
zinc deficient untreated mice (P < 0.05, Fig. 3.4A). Rosiglitazone treatment significantly
reduced iNOS mRNA expression in abdominal aorta only in zinc adequate mice (P <
0.05, Fig. 3.4A) but not in zinc deficient mice.
Zinc deficiency alone did not increase MCP-1 mRNA expression (Fig. 3.4B).
Rosiglitazone treatment had a significant interaction with zinc status by tending to
increase MCP-1 mRNA expression in zinc deficient mice and decrease MCP-1 mRNA
expression in zinc adequate mice (P < 0.05, Fig. 3.4B). During zinc deficiency,
rosiglitazone treatment significantly up-regulated MCP-1 mRNA in abdominal aorta
compared to rosiglitazone treated zinc adequate mice (P < 0.05, Fig. 3.4B).

The effects of rosiglitazone on IκBα protein expression in LDL-R-/- mice are regulated
by zinc status
The zinc deficient LDL-R-/- mice had lower levels of liver IκBα protein
expression than the zinc adequate mice (P < 0.01, Fig. 3.5). Regulation of liver IκBα
protein expression was affected by both treatments with rosiglitazone and zinc, and the
treatment interaction was statistically significant. Specifically, IκBα protein expression
in liver of LDL-R-/- mice was up-regulated by rosiglitazone in zinc adequate mice but not
in zinc deficient mice (P < 0.05, Fig. 3.5).

Zinc deficiency and rosiglitazone increase PPAR DNA binding activity in LDL-R-/mice
NF-κB DNA binding activity in LDL-R-/- mice liver was unaffected by either zinc
intake or rosiglitazone treatment (Fig. 3.6A). However, rosiglitazone tended to increase
NF-κB DNA binding activity during zinc deficiency and decrease it during zinc adequacy
(Fig. 3.6A). Zinc deficiency resulted in higher PPAR DNA binding activity in mice liver
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(P < 0.05, Fig. 3.6B). Rosiglitazone treatment also increased PPAR DNA binding
activity in mice liver (P < 0.05, Fig. 3.6B).

The effects of rosiglitazone on concentrations of plasma anti- and pro-inflammatory
cytokines in LDL-R-/- mice are regulated by zinc status
Zinc deficiency resulted in lower plasma IL-10 concentrations in LDL-R-/- mice
(P < 0.01, Table 3.2). Although statistically not significant, treatment with rosiglitazone
tended to increase circulating anti-inflammatory cytokine (IL-4, IL-10, IL-13)
concentrations during zinc adequacy and tended to decrease them during zinc deficiency
(Table 3.2).
Zinc deficiency resulted in lower plasma IL-1α concentrations (P < 0.001, Table
3.3) and higher plasma IL-6 concentrations (P < 0.05, Table 3.3) in LDL-R-/- mice.
Rosiglitazone tended to further increase IL-6 concentrations in zinc deficient mice and
slightly decrease them in zinc adequate mice (P = 0.095, Table 3.3). Zinc and
rosiglitazone had a significant interaction in affecting plasma IL-12 concentrations (P <
0.01, Table 3.3). Specifically, rosiglitazone treatment decreased plasma IL-12
concentrations during zinc adequacy (P < 0.01, Table 3.3), but tended to increase IL-12
concentrations during zinc deficiency (Table 3.3).

3.5

Discussion
This study was designed to investigate the interaction of a modest zinc depletion

and dietary fat intake on the response to rosiglitazone in mice lacking LDL-R. To our
knowledge, this is the first study to investigate the effect of rosiglitazone and dietary zinc
depletion in this strain of mice.
Growth retardation is well known to be one of the major symptoms of zinc
deficiency in the human being [4]. In the current study, the mice were on either a zincdeficient or a zinc-adequate diet in powder form. Apparently it took some time for the
mice to adjust themselves to the powder-formed experimental diets, which could explain
why the body weight was generally not changed until day 9. After that, only mice on the
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zinc-adequate diet gained weight, contrasting the almost unchanged body weight of the
zinc-deficient mice.
Based on our preliminary study with LDL-R normal mice and the short duration
of the study, we did not expect plasma zinc concentrations to be significantly affected.
And in fact, plasma zinc levels were not different between mice fed the zinc depleted
compared to the zinc adequate diets regardless of rosiglitazone treatment. However,
within the dietary zinc groups (0 zinc or 30 zinc) rosiglitazone treatment increased
plasma zinc levels. We verified that the rosiglitazone solution was zinc-free, therefore
this repartitioning of plasma zinc by rosiglitazone appears to be a specific effect of the
drug. Liver zinc concentration is considered to be more responsive to dietary zinc intake
than plasma zinc [108] and indeed we observed lower liver zinc concentrations in mice
fed the low compared to the adequate zinc diet. However, with rosiglitazone treatment
liver zinc was reduced only in the mice fed the zinc adequate diet. The observation that
rosiglitazone increased plasma zinc in both dietary groups suggests that other body zinc
stores besides liver may be mobilized by rosiglitazone, and this observation is worthy of
further study.
The present in vivo study generally supports the in vitro finding of PPAR
dysregulation during zinc deficiency. For example, rosiglitazone treatment significantly
down-regulated iNOS gene expression in abdominal aorta only in zinc adequate mice,
indicating that only under zinc adequate condition is PPARγ functioning properly to
inhibit NF-κB activity. The pro-inflammatory gene iNOS is regulated by NF-κB [88].
During inflammation, smooth muscle cells and macrophages express iNOS thus causing
an increase in NO generation. NO can react with O2• – to produce the strong oxidant
ONOO–, which in turn can increase lipid peroxidation, protein nitration, and LDL
oxidation, contributing to the pathogenesis of atherosclerosis [83]. Interestingly, in the
current study, the zinc adequate mice had unexpected higher basal levels of iNOS mRNA
expression in abdominal aorta, which could be due to the high-fat feeding. In our
preliminary work using the same mouse model with low-fat diet feeding, iNOS mRNA
expression in abdominal aorta were higher in the zinc-deficient mice than in the zincadequate mice (see Appendix, Fig. I). In the present study, MCP-1 mRNA expression
was also observed to be higher in rosiglitazone treated zinc deficient mice than in
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rosiglitazone treated zinc adequate mice. This “adverse” effect of rosiglitazone during
zinc deficiency again suggests that proper anti-inflammatory properties of PPARγ are
compromised during zinc deficiency. MCP-1 is a potent chemoattractant for monocytes
and plays an important role in monocyte recruitment and endothelium activation. The
expression of MCP-1 by endothelial cells is NF-κB regulated [109].
Both zinc and metallothioneins (MT) can protect cells against redox stress [110].
MT are intracellular cysteine-rich transition metal binding proteins critical in maintaining
cellular zinc homeostasis [17]. MT have zinc-buffering and anti-oxidant properties [17,
18, 110] and might prevent diabetic cardiovascular complications [111]. In the current in
vivo study, zinc deficiency tended to down-regulate liver MT1 mRNA expression
compared to zinc adequate mice (see Appendix, Fig. II). Furthermore, rosiglitazone
significantly up-regulated liver MT1 mRNA expression in mice regardless of the zinc
status (see Appendix, Fig. II), suggesting that the anti-inflammatory and anti-atherogenic
properties of rosiglitazone could be in part due to its induction of MT.
Another critical element in the etiology of atherosclerosis is via regulation by
cytokines [112]. There are basically two categories of cytokines, i.e. pro-inflammatory
cytokines, which promote inflammation, such as IL-1, TNF, and IL-6; and antiinflammatory cytokines, which inhibit the activity of pro-inflammatory cytokines, such as
IL-4, IL-10, and IL-13 [113, 114]. Epidemiological studies have shown that plasma IL-6
level is a potent independent predictor of risk of future cardiovascular events [93]. IL-6
exhibits its main inflammatory properties in the acute phase response by promoting the
production of a variety of hepatic acute phase proteins [93, 115]. Elevated levels of IL-6
also have been found in both human and mice atherosclerotic lesions and can act in a proinflammatory and pro-coagulant way, thus contributing to lesion progression and
thrombotic complications [93]. On the other hand, IL-10 is an important antiinflammatory cytokine which inhibits the production of pro-inflammatory
monocyte/macrophage and neutrophil cytokines, and pro-atherogenic T-helper 1 (Th1)
lymphocyte cytokines [114, 116]. By deactivating pro-inflammatory cytokines and
iNOS, IL-10 has anti-inflammatory properties on cardiovascular tissues [117]. In the
present study, zinc deficiency significantly elevated the pro-inflammatory IL-6 and
decreased the anti-inflammatory IL-10 levels in plasma. IL-12 is an immunoregulatory
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cytokine that favors Th1 cell phenotype and induces Th1 cytokines, such as INFγ and IL2. By regulating cell mediated immunity and activating macrophages, the Th1 cytokines
contribute to the development of atherosclerosis [114, 116]. In the current study,
rosiglitazone had a significant interaction with zinc status to regulate plasma IL-12 levels
by decreasing it during zinc adequacy and increasing it during zinc deficiency, which
indicates that the proper anti-inflammatory effect of the PPARγ agonist rosiglitazone
requires zinc.
An earlier research in our lab utilizing the same mouse model (i.e. LDL-R-/- mice)
has revealed that zinc deficiency can increase pro-atherosclerotic markers, such as NF-κB
DNA binding and vascular cell adhesion molecule-1 (VCAM-1) expression, and
decrease PPARγ DNA binding in these animals [118]. In the current study, the
expression of IκBα protein in liver tissue was elevated by rosiglitazone only in zinc
adequate mice but not in zinc deficient mice, suggesting that rosiglitazone exerts its antiinflammatory effect by up-regulating IκBα only during zinc adequacy. IκBα is a natural
inhibitor of NF-κB. By interacting with and shielding the nuclear localization signal of
NF-κB, IκBα prevents the translocation of NF-κB to the nucleus and its DNA binding
[119, 120]. IκBα is also able to dissociate prebound NF-κB from its cognate DNA
binding sites [119]. In the current study, NF-κB DNA binding activity in liver tissue was
not significantly affected by either zinc status or rosiglitazone. However, rosiglitazone
tended to decrease NF-κB DNA binding during zinc adequacy, a trend that was reversed
during zinc deficiency. The NF-κB DNA binding activity data seem to be consistent
with the IκBα protein expression data. Together they can partially explain the observed
iNOS and MCP-1 gene expression patterns in these LDL-R-/- mice. In the present study,
interestingly, both PPARγ mRNA expression in abdominal aorta (see Appendix, Fig. III)
and PPAR DNA binding activity in liver were higher in zinc deficient mice, suggesting a
compensatory process in these mice, i.e. up-regulation of the anti-inflammatory
transcription factor PPAR and its DNA binding activity against decreased PPAR
signaling. A similar phenomenon of increased PPARγ mRNA level in thoracic aorta
during zinc deficiency was observed earlier in a study using the same mouse model
[118]. Taken together, these in vivo studies suggest that adequate zinc is crucial in
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providing an overall anti-inflammatory environment by inhibiting NF-κB and by
activating protective PPAR signaling.
In conclusion, our present in vivo study suggests that zinc deficiency intensifies
pro-inflammatory and impairs anti-inflammatory events in the atherogenic LDL-R-/mouse model by activating NF-κB pathway and compromising PPAR function. The in
vivo data are generally in accordance with the in vitro findings made in endothelial cells
as has been described in Chapter Two (Fig. 3.7). Adequate dietary zinc intake is
therefore recommended in patients treated with rosiglitazone to ameliorate inflammatory
and atherosclerotic events.
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Table 3.1. Experimental diets 1
Ingredient

LF / 0 Zn

HF / 0 Zn

LF /30 Zn

HF /30 Zn

g/kg
Egg white

200

200

200

200

3

3

3

3

2.5

2.5

2.5

2.5

397.5

397.5

397.5

397.5

Sucrose

100

100

100

100

Dyetrose

131

51

121

41

Cellulose

35

35

35

35

Corn oil

50

130

50

130

Safflower oil

20

20

20

20

2

DL-Methionine
Choline bitartrate
Corn starch

50

50

50

50

3,4

0

0

10

10

Vitamin Mix AIN-93

10

10

10

10

Biotin mix5

1

1

1

1

Mineral Mix
Zinc Mix

1

Diet ingredients were purchased from MP Biomedicals, Salon, OH except for dyetrose which

was purchased from Dyets Inc., Bethlehem, PA, and corn starch, sucrose, and corn oil which
were purchased from a local food supply warehouse.
2

A mineral mix was prepared using elemental compounds in cornstarch to provide a zinc

depleted mixture [105, 106].
3

Zinc carbonate was mixed with dyetrose and added to provide the desired final concentrations in

the diets.
4

Actual zinc concentrations of the zinc-deficient and zinc-adequate diets determined by atomic

absorption were 0.4 ± 0.1 and 33.1 ± 0.3 mg/kg, respectively.
5

Biotin was mixed with dyetrose and added to provide 0.005 g biotin/g egg white protein.
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Table 3.2. Effects of dietary zinc status and rosiglitazone on selected plasma antiinflammatory cytokine concentrations in LDL-R-/- mice1
P-values 2
Cytokine

0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG

Overall

Zn

RSG

pg/mL
IL-4 3

7.1 ± 0.3

6.6 ± 0.3

6.7 ± 0.3

7.0 ± 0.3

0.602

0.955

0.622

IL-10

4

53.9 ± 8.3

51.4 ± 7.3

67.3 ± 8.0

85.3 ± 7.6

0.012

0.004

0.323

IL-13

4

179.5 ± 9.3

166.2 ± 8.2

163.3 ± 8.9

173.3 ± 8.9

0.675

0.730

0.718

1

Values are means ± SEM.

2

P-values from two-way ANOVA. Zn × RSG interactions were not significant, P > 0.05.

3

n = 10-14.

4

n = 10-13.
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Table 3.3. Effects of dietary zinc status and rosiglitazone on selected plasma proinflammatory cytokine/chemokine concentrations in LDL-R-/- mice 1
P-values 2
Cytokine/
Chemokine

0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG Overall

Zn

RSG Zn×RSG

pg/mL
IL -1α 3

12.1±3.0

16.0±2.5

26.6±2.8

25.5±2.7

0.001

<0.001 0.604

*

IL -2 3

25.8±4.1

24.2±3.4

20.6±3.7

23.2±3.7

0.801

0.406 0.891

*

IL -6 4

60.6±5.5

76.7±4.9

57.3±4.5

56.6±4.7

0.018

0.023 0.124

0.095

0.002

0.076 0.072

0.001

b

b

a

b

IL -12 5

105.0±15.9

IL -17 6

20.3±2.0

16.7±1.7

18.5±1.8

16.2±1.9

0.428

0.537 0.116

*

TNFα 6

15.0±2.6

16.0±2.1

13.2±2.3

10.7±2.5

0.419

0.146 0.752

*

MCP-1 5

85.3±44.4

145.2±34.4

98.1±36.9

110.8±40.1

0.700

0.784 0.359

*

130.6±12.3

184.2±15.0

104.6±15.0

1

Values are means ± SEM.

2

P-values from two-way ANOVA. Means without a common letter differ (a > b), P < 0.01. * Zn

× RSG interactions were not significant, P > 0.05.
3

n = 10-14.

4

n = 9-13.

5

n = 9-15.

6

n = 10-15.
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Figure 3.1. Treatment of the LDL-R-/- mice.
LDL-R-/- mice were fed a low-fat diet with either 0 or 30 mg/kg of zinc. After 3 wk of
feeding the low-fat diet, all mice were fed a high-fat diet for 1 wk, without changing the
original zinc nutritional status. Rosiglitazone (20 mg/kg/d) or the vehicle (0.25% of
methylcellulose) was administered by gavage once per day for 9 d, which was initiated 2
d prior to the start of the high-fat regimen. LF, low-fat; HF, high-fat. 0 Zn, 0.4 mg/kg of
zinc; 30 Zn, 33.1 mg/kg of zinc. RSG, rosiglitazone.
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0 Zn
0 Zn + RSG
30 Zn
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Body Weight (g)
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Figure 3.2. Body weight changes of the LDL-R-/- mice.
Values are means ± SEM, n = 10-15.
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20

22

24

26

28

0.4
0.3

Plasma
Overall
Zn
RSG
Zn x RSG

b

Liver

P -values
Plasma
Liver
< 0.001
< 0.001
0.143
< 0.001
< 0.001
0.056
*
0.019

0.5
a

0.4
b

0.3

b

0.2

0.2

0.1

0.1

0.0

0.0
0 Zn

0Zn + RSG

30 Zn

Liver Zinc Concentration
(mmol/kg)

Plasma Zinc Concentration
(mmol/L)

0.5

30Zn + RSG

Figure 3.3. Effects of dietary zinc status and rosiglitazone on plasma and liver zinc
levels in LDL-R-/- mice.
Values are means ± SEM, n = 9-15. Means without a common letter differ (a > b), P <
0.01. * Zn × RSG interaction was not significant (P > 0.05).

53

A
0.9
0.8

iNOS mRNA

0.7
0.6

Overall
Zn
RSG
Zn × RSG

P-values
< 0.001
0.138
0.002
< 0.001

a

ab

b

0.5

b

0.4
0.3
0.2
0.1
0.0
0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG

Figure 3.4. Effects of dietary zinc status and rosiglitazone on iNOS (A) and MCP-1
(B) gene expression in LDL-R-/- mice.
The vertical axis in each graph represents relative units, calculated as the ratio of the copy
number of the target gene over the copy number of the endogenous control (18S rRNA
and β-actin, respectively). Values are means ± SEM, n = 7-9. Means without a common
letter differ (a > b), P < 0.05.
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Zn × RSG
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P-values
0.015
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Figure 3.4 (Continued)
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30 Zn

30 Zn + RSG

6

Iκ Bα Protein

5

Overall
Zn
RSG
Zn × RSG

P-values
0.010
0.008
0.121
0.024

a

4
3
b

2
b
1

b

0
0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG

ΙκΒα
β-actin

Figure 3.5. Effects of dietary zinc status and rosiglitazone on IκBα protein
expression in LDL-R-/- mice
The values are ratios of the densitometric units of IκBα over those of β-actin. Values
are means ± SEM, n = 3. Means without a common letter differ (a > b), P < 0.05. The
gel data are a representative of the typical outcome of three repeated Western blot
experiments.

56

A

NF-κ B DNA Binding Activity

70

Overall
Zn
RSG
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P-values
0.724
0.501
0.708

50
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0
0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG

NF-κB

Figure 3.6. Effects of dietary zinc status and rosiglitazone on NF-κB (A) and PPAR
(B) DNA binding activities in LDL-R-/- mice.
The vertical axis in each graph represents densitometric units. Values are means ± SEM,
n = 3. The gel data are representatives of the typical outcome of three repeated EMSA
experiments for NF-κB and PPAR, respectively.
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PPAR DNA Binding Activity
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Overall
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RSG
Zn × RSG
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P-values
0.010
0.015
0.014
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0
0 Zn

0 Zn + RSG
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Figure 3.6 (Continued)
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30 Zn

30 Zn + RSG

Figure 3.7. Proposed mechanism of pro-inflammatory environment and endothelial
cell activation during zinc deficiency.
Zinc deficiency induces an increase in cellular oxidative stress, activation of NF-κB and
induction of inflammatory cytokines and adhesion molecules. The anti-inflammatory
properties of PPARs are blocked in part by zinc deficiency, further contributing to
inflammation and monocyte adhesion to activated endothelial cell. The apparent
imbalance of NF-κB and PPAR signaling during zinc deficiency may be a major risk
factor of atherosclerosis.
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Chaper 4. Zinc Deficiency Alters Lipid Metabolism in LDL-ReceptorDeficient Mice Treated with Rosiglitazone
4.1

Synopsis
Zinc is a structural and functional component of PPAR and zinc deficiency may

be associated with an increased risk for cardiovascular diseases. We tested the
hypothesis that zinc deficiency compromises lipid metabolism in rosiglitazone-treated
mice lacking the functional LDL-R gene. LDL-R deficient (LDL-R-/-) mice were
maintained for three weeks on low-fat (7g/100g) diets that were either zinc deficient or
zinc adequate. Subsequently, diets were adjusted to a high-fat (15g/100g) regimen for
one week to produce a biological environment of mild oxidative and inflammatory stress.
Half of the mice within each zinc group were gavaged daily with the PPARγ agonist
rosiglitazone, starting two days prior to the high-fat feeding. Selected lipid parameters
were studied. Zinc deficiency increased plasma total cholesterol, which was also
elevated by rosiglitazone. Zinc deficiency also caused an increased lipoproteincholesterol distribution towards the non-HDL fraction (VLDL, intermediate density
lipoprotein, LDL). Plasma total fatty acids tended to be increased during zinc deficiency,
and rosiglitazone treatment resulted in similar changes in the fatty acid profile in zinc
deficient mice. Fatty acid translocase (FAT/CD36) expression in abdominal aorta was
up-regulated by rosiglitazone only in zinc-deficient mice. In contrast, rosiglitazone
treatment markedly increased lipoprotein lipase (LPL) expression only in zinc-adequate
mice. These data suggest that in this atherogenic mouse model treated with rosiglitazone,
lipid metabolism can be compromised during zinc deficiency, and that adequate dietary
zinc may be considered during therapy with the anti-diabetic medicine rosiglitazone.

4.2

Introduction
Cardiovascular diseases are a major health problem in industrialized countries and

have a rising incidence in the non-industrialized part of the world as well. Causes for the
development of atherosclerosis are usually of multiple nature. Lifestyle and nutrition can
be closely linked to the onset and the pace of progression of atherosclerotic events [121,
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122]. Hyperlipidemia, central obesity, impaired glucose tolerance and overall insulin
resistance are among the many risk factors associated with accelerated pathology of
atherosclerosis [123].
Studies in rodent models suggest that zinc supplementation is effective for
reducing the incidence of both Type I and Type II diabetes [124], and that zinc deficiency
can activate stress pathways resulting in loss of insulin sensitivity [125]. Evidence also
suggests that Type II diabetic patients experience zinc malabsorption and increased
excretion of urinary zinc [6].
Synthetic PPARγ agonists, such as thiazolidinediones (including rosiglitazone and
pioglitazone), improve insulin sensitivity and glycemic control in type II diabetes and
may reduce atherosclerosis progression in patients with diabetes [126, 127]. Protective
mechanisms of PPARγ agonists may include favorable changes in plasma lipoprotein
profiles and inflammatory markers. For example, rosiglitazone can raise HDLcholesterol levels and lower C-reactive protein levels in patients with type II diabetes [96,
101, 128]. Rosiglitazone also is able to lower postprandial triglyceride levels in patients
with type II diabetes, without changes in fasting plasma triglycerides [129]. However,
favorable lipid effects of rosiglitazone may not be as apparent in nondiabetic patients.
Even though rosiglitazone can lower plasma concentrations of C-reactive protein and IL6, it also can increase total cholesterol [103], as well as LDL cholesterol and triglyceride
levels [130] in nondiabetic patients. Other endogenous or exogenous factors, such as the
overall nutritional status of a patient, may play a role in the effectiveness of PPAR
agonists as a broad antiatherogenic agent [131].
There is evidence that zinc can modulate PPAR signaling [25]. The DNAbinding domain (DBD) of PPAR has two sets of zinc fingers [22]. The specificity and
polarity of PPAR-DNA binding seems to be at least in part due to features in the zinc
finger domains of PPAR [132]. The DNA binding partner of PPAR, retinoid X receptor
(RXR), also has a DBD with two zinc fingers involved [24]. Upon ligand activation,
PPAR heterodimerizes with RXR and binds to PPAR response elements (PPRE) within
the promoter region of target genes, thereby regulating or transactivating their expression
[133]. As zinc is an essential constituent of the DBD of both PPAR and RXR, zinc
deficiency could impair the function of this transcription factor complex.
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Zinc fingers also have been described to mediate protein-lipid interactions. Zinccontaining FYVE domains are specific in recognizing and binding phosphatidylinositol3-phosphate (PtdIns3P), a component of cell membrane [134]. It is thus very likely that
zinc plays a critical role in PPAR signaling and associated regulation of cellular lipid
metabolism. Thus, the objective of the present study was to explore the role of zinc in
the antiatherogenic properties of the PPARγ ligand rosiglitazone, with a focus on selected
lipid parameters in an atherogenic mouse model. We hypothesize that PPAR signaling
and associated lipid metabolism are compromised during zinc deficiency and that
adequate dietary zinc may be critical to maintain favorable lipid effects of the antidiabetic medicine rosiglitazone.

4.3

Materials and Methods

Animals and diets (See Chapter Three)
Sufficient plasma samples were not available from all animals for glucose
analysis, resulting in variations in sample size as outlined.

Zinc quantification (See Chapter Three)

Measurement of plasma cholesterol and lipoprotein-cholesterol distribution
Plasma total cholesterol content was determined enzymatically using a
commercially available kit, Wako Cholesterol E (Wako Chemicals USA, Inc., Richmond,
VA). Plasma cholesterol distribution in different lipoprotein fractions was measured by
Jessica Moorleghen at the University of Kentucky Cardiovascular Research Center using
fast-performance liquid chromatography (FPLC) utilizing a Biologic DuoFlow System
(Bio-Rad Laboratories, Hercules, CA) equipped with a SuperoseTM 6HR 10/30 column
(Amersham Pharmacia Biotech AB, Uppsala, Sweden) [135].
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Analysis of plasma fatty acids
Plasma total lipids were extracted with chloroform [136] followed by methyl
esterification of total fatty acids with BF3/Methanol (Supelco, Bellefonte, PA). Analysis
of fatty acids was performed by Dr. Xiang-an Li at the University of Kentucky
Department of Pediatrics using a gas chromatography system, Agilent 6890 GC G2579A
system (Agilent, Palo Alto, CA) equipped with an OMEGAWAXTM 250 capillary
column (Supelco, Bellefonte, PA) and a flame ionization detector. An Agilent 5973
network mass selective detector (Agilent, Palo Alto, CA) was used to identify target
peaks. Heptadecanoic acid (17:0) was used as an internal standard for data analysis.

Real-time RT-PCR
Abdominal aorta and liver were excised from the mice, immerged in RNAlater
(Qiagen, Valencia, CA) and stored at -80° C until analysis. Total RNA was isolated from
abdominal aorta using RNeasy Fibrous Tissue Mini Kit (Qiagen, Valencia, CA) after
surrounding adipose and connective tissues were removed, and total RNA was isolated
from liver using RNeasy Mini Kit (Qiagen, Valencia, CA). cDNA was generated using
the Reverse Transcription System (Promega, Madison, WI). Gene expression was
determined by real-time PCR using the ABI Prism 7300 Real Time PCR System
(Applied Biosystems, Branchburg, NJ) and TaqMan® Universal PCR Master Mix, No
AmpErase® UNG (Applied Biosystems, Branchburg, NJ). TaqMan® gene expression
assays were used for mouse fatty acid translocase (FAT/CD36), and lipoprotein lipase
(LPL) (Mm00432403_m1, and Mm 00434764_m1, Applied Biosystems, Branchburg,
NJ). Each assay consisted of a specific pair of unlabeled PCR primers and a specific
TaqMan® MGB probe which was 5’ end labeled with a FAMTM reporter dye and 3’ end
labeled with a minor groove binder/non-fluorescent quencher (MGBNFQ). Detection of
18S rRNA, or β-actin as endogenous control, utilized pre-developed Taqman® assay
reagents, i.e. Eukaryotic 18S rRNA Endogenous Control, or Mouse ACTB Endogenous
Control (Applied Biosystems, Branchburg, NJ).
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Measurement of plasma glucose
Plasma glucose concentration was determined using glucose oxidase/peroxidase
(PGO enzymes) (Sigma-Aldrich, Saint Louis, MO) and o-dianisidine dihydrochloride
(Sigma-Aldrich, Saint Louis, MO) according to the manufacturer’s instruction. The
amount of glucose in the test sample was determined by measurement of the absorbance
at 450 nm using a SpectraMax® M2 microplate reader (Molecular Devices Corporation,
Sunnyvale, CA).

Statistical analysis (See Chapter Three)

4.4

Results
Rosiglitazone treatment contributed to a predictable biological outcome by

affecting plasma insulin and adiponectin concentrations. Administration of rosiglitazone
resulted in a 36 % decrease in plasma insulin concentrations and a 2-fold increase in
adiponectin concentrations (Table 4.1).

Zinc deficiency elevates plasma total cholesterol in LDL-R-/- mice
The zinc-deficient diet led to higher concentrations of plasma total cholesterol in
LDL-R-/- mice compared with the zinc-adequate diet (Fig. 4.1). Treatment with
rosiglitazone increased the concentration of plasma total cholesterol (Fig. 4.1).

Zinc deficiency increases non-HDL cholesterol distribution in LDL-R-/- mice
Consistent with the data on plasma total cholesterol, zinc deficiency increased
concentrations of plasma cholesterol contained in the non-HDL fraction [VLDL,
intermediate density lipoprotein (IDL), LDL] as compared with zinc-adequate mice (area
under the curves; P < 0.001, Fig. 4.2). In contrast, levels of HDL cholesterol were similar
in all mice independent of the dietary zinc intake (Fig. 4.2). Rosiglitazone treatment had
no effect on lipoprotein-cholesterol profile under either zinc-adequate or zinc-deficient
conditions (Fig. 4.2).
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Zinc deficiency elevates plasma fatty acid concentrations in LDL-R-/- mice
The major plasma fatty acids are palmitic acid (16:0), stearic acid (18:0), oleic
acid (18:1), linoleic acid (18:2), and arachidonic acid (20:4), which add up to about 90%
of total plasma fatty acids [137]. Plasma total fatty acids in LDL-R-/- mice tended to be
increased during zinc deficiency (P = 0.080, Table 4.2). Detailed analysis of the fatty
acid profile revealed that the patterns of fatty acid changes due to rosiglitazone treatment
(except for 20:4) were similar and that elevated levels of 18:0 and 18:1 in zinc-deficient
LDL-R-/- mice were mostly responsible for the increased total fatty acid levels (Table
4.2).

The effects of rosiglitazone on expression of genes associated with lipid uptake and
metabolism in LDL-R-/- mice are regulated by zinc status
LPL is an enzyme which hydrolyses triglyceride-rich lipoproteins and CD36
mediates cellular uptake of free fatty acids. Zinc status did not affect the baseline LPL
and CD36 mRNA expression (Fig. 4.3). Treatment with rosiglitazone up-regulated LPL
mRNA expression in livers (P < 0.05, Fig. 4.3).
The effects of rosiglitazone on CD36 gene expression in abdominal aortas were
also regulated by zinc status. Specifically, CD36 mRNA levels were significantly
increased (1.75 fold) in zinc-deficient LDL-R-/- mice which received rosiglitazone
treatment (P < 0.05, Fig. 4.3). These effects were not observed in zinc-adequate mice
(Fig. 4.3).

4.5

Discussion
Zinc is critical for normal function of numerous proteins. Thus, a change in

cellular zinc status can affect multiple cellular events. Because PPARs play a role in
lipid transport and metabolism [138], lack of zinc appears to result in dysfunctional
PPAR signaling with a subsequent detrimental lipid metabolism. PPARγ activation by its
endogenous or exogenous ligands, such as TZDs, up-regulates the expression of
adiponectin, a PPARγ target gene [139], which promotes insulin sensitivity and down-
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regulates inflammatory cytokines and thus decreases insulin resistance [131, 140]. Most
of all, PPARγ activates numerous genes involved in lipid storage and lipogenesis [131]
and in particular in the cellular assimilation of lipids via anabolic pathways [141].
Whether or not the overall antiatherogenic properties of PPARγ agonists are due to
favorable lipid changes or anti-inflammatory properties is not clear. However, protection
against cardiovascular complications by PPARγ agonists is well accepted. For example,
rosiglitazone, a PPARγ agonist, strongly inhibited the development of atherosclerosis in
LDL-R-/- mice [99].
The role of zinc deficiency in atherosclerosis is not well defined; however,
epidemiological studies suggest that in some population groups, low serum
concentrations of zinc are associated with coronary artery disease [67]. Although
controversy still exists about the effect of zinc on human lipoprotein metabolism, some
studies confirmed the lipid lowering effects of zinc in humans. Oral zinc
supplementation decreased total and LDL cholesterol, while HDL cholesterol increased
in both normal and diabetic humans [142, 143]. Other studies, however, found that zinc
supplementation had little effect on lipoprotein profiles [144] or decreased HDL
cholesterol [145, 146].
In the present in vivo study, we provide evidence that PPARγ-regulated gene
expression and associated lipid metabolism are compromised during zinc deficiency and
that adequate dietary zinc may be critical to maintain favorable lipid effects of
rosiglitazone. Treatment with rosiglitazone tended to increase plasma total cholesterol
more in zinc-deficient mice. Such lipid change is atherogenic and suggests that any
possible favorable lipid profile induced by rosiglitazone treatment may be compromised
during zinc deficiency. Furthermore, zinc deficiency alone caused a shift of lipoproteincholesterol distribution to the non-HDL (VLDL, IDL, and LDL) fraction. This is
consistent with our previous findings that zinc deficiency can increase plasma lipids and
atherosclerotic markers in LDL-R-/- mice [118].
Although many studies suggest that treatment with PPARγ agonists such as
rosiglitazone stabilizes or improves plasma lipid parameters, especially in diabetic
patients [102, 147, 148], other studies reported significantly increased triglycerides
following treatment with rosiglitazone [130, 149, 150]. In the LDL-R-/- mouse model, we
66

observed an elevation of total plasma fatty acids in zinc-deficient mice treated with
rosiglitazone. All major plasma fatty acids appeared to be elevated in the zinc-deficient
group receiving rosiglitazone. There is clear evidence that hypertriglyceridemia is an
independent risk factor of cardiovascular diseases such as atherosclerosis [65, 151].
Furthermore, triglyceride-rich lipoproteins and free fatty acids are often elevated in
patients with type II diabetes, and thus a major risk factor [152, 153].
Our data suggest that expression of the LPL gene, which is a PPARγ target gene
[154], and is also critical in the clearance of triglyceride-rich lipoproteins, was upregulated in zinc-adequate mice upon treatment with rosiglitazone. Other researchers
observed similar results in brown adipose tissue of rodents treated with this PPARγ
agonist [147]. In contrast, mRNA expression of LPL was minimally up-regulated in
zinc-deficient mice as a result of rosiglitazone treatment, which may be due to
compromised PPARγ function. Because LPL is critical in clearance of triglyceride-rich
lipoproteins, and is able to limit inflammation by generating endogenous PPARα ligands
(thus mediating PPARα activation) [155], dysfunction of this gene due to zinc deficiency
could further contribute to lipid risk factors of atherosclerosis.
Scavenger receptors like CD36 are important in the early pathology of
atherosclerosis, which includes macrophage uptake of modified LDL and foam cell
formation [156]. In fact, the absence of CD36 in the atherogenic ApoE-deficient mice
maintained on a high fat diet resulted in a marked decrease in total lesion area in the
aortic tree, which could be due to the decreased uptake of oxidized LDL by macrophages
[156]. There is also evidence that an increase in CD36 is caused by defective insulin
signaling and that administration of PPARγ agonists can decrease CD36 protein [157]. In
our study, CD36 gene expression in abdominal aorta was significantly up-regulated by
rosiglitazone only in zinc-deficient mice, suggesting accelerated uptake of lipids and
especially pro-oxidative and pro-inflammatory fatty acids, such as linoleic acid and
arachidonic acid. In contrast, in another study, rosiglitazone up-regulated aortic CD36
mRNA in mice consuming a high-cholesterol diet [99]. There is evidence using human
macrophages that CD36 up-regulation by darglitazone, another PPARγ ligand, is
modified by the presence or absence of physiological concentrations of albumin-bound
oleic or linoleic acid [158]. In the present study, rosiglitazone treatment resulted in
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elevated levels of plasma total cholesterol and total fatty acids in zinc deficient mice,
which could increase cellular oxidative stress. This may be sufficient to activate the
redox-sensitive transcription factor nuclear factor erythroid-2 related factor 2 (Nrf2)
[159], which is another important transcription factor involved in the induction of CD36
besides PPARγ [160]. Indeed oxidative stress has been found to increase the expression
of CD36 in macrophages from atherosclerotic mice [161]. Therefore, the up-regulation
of CD36 by rosiglitazone in zinc deficient mice could be due in part to the activation of
Nrf2 caused by increased oxidative stress. Our data suggest that treatment with
rosiglitazone during a nutritional state of zinc deficiency may increase, rather than
decrease, hyperlipidemic risk factors.
There are some unexpected results in this study. For example, the similar effects
of rosiglitazone on adiponectin levels in mice on either zinc deficient or zinc adequate
diets suggest that adiponectin gene expression may be only partially regulated by a
PPARγ-dependent pathway and that rosiglitazone may also regulate the expression of
adiponectin via PPARγ-independent pathways [162]. Therefore, it is likely that some
PPARγ-independent pathway which is not zinc dependent contributed to the observed
effects of rosiglitazone treatment on adiponectin levels.
In summary, we are providing in vivo evidence that zinc deficiency interacts with
rosiglitazone treatment to induce selected proatherogenic lipid profiles in LDL-R-/- mice.
Our data also illustrate that adequate dietary zinc is critical for preventing or minimizing
some possible side effects of antidiabetic PPARγ agonists. For example, CD36 gene
expression in abdominal aorta was significantly up-regulated by rosiglitazone only in
zinc-deficient mice. Even though not statistically significant, treatment with
rosiglitazone tended to increase plasma total cholesterol and fatty acids more when mice
were zinc deficient. Because dietary zinc intake of certain population groups is still
below intake recommendations [163], these data emphasize the importance of adequate
dietary zinc in humans during treatment phases associated with diabetes and other
cardiovascular risk factors.
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Table 4.1. Effects of dietary zinc status and rosiglitazone on plasma glucose, insulin,
and adiponectin concentrations in LDL-R-/- mice 1

P-values 2

Glucose
mmol/L

3

4

Insulin
pmol/L

Adiponectin
nmol/L

4

0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG

15.6±1.6

13.1±0.9

17.2±0.9

16.0±1.1

0.0076 0.0319 0.1455

118.5±18.1

78.5±16.7

176.3±18.1

110.6±16.7

0.0024 0.0176 0.0055

511.2±121.5 1495.5±112.2

328.2±121.5 1056.6±121.5

Overall

Zn

0.0001 0.0149 0.0001

1

Values are means ± SEM.

2

P-values from two-way ANOVA. Zn × RSG interactions were not significant, P > 0.05.

3

n = 4–14.

4

n = 6–7.
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RSG

Table 4.2. Effects of dietary zinc status and rosiglitazone on plasma total and
individual fatty acid concentrations in LDL-R-/- mice 1

P-values 2
Fatty
acid

0 Zn

0 Zn + RSG

30 Zn

30 Zn + RSG

Overall

Zn

RSG

mmol/L
Total

9.39 ± 0.61 11.15 ± 0.56

8.67 ± 0.83

9.25 ± 0.78

0.062

0.080

0.150

16:0

1.85 ± 0.16

1.69 ± 0.13

1.82 ± 0.13

0.039

0.059

0.115

18:0

1.23 ± 0.17

1.36 ± 0.14

0.95 ± 0.13

0.90 ± 0.14

0.045

0.015

0.837

18:1

1.52 ± 0.14

1.82 ± 0.12

1.10 ± 0.11

1.35 ± 0.12

< 0.001

< 0.001

0.031

18:2

3.40 ± 0.33

4.22 ± 0.28

3.38 ± 0.26

3.55 ± 0.28

0.128

0.232

0.130

20:4

1.40 ± 0.16

1.56 ± 0.14

1.55 ± 0.13

1.63 ± 0.14

0.557

0.453

0.393

2.19 ± 0.13

1

Values are means ± SEM, n = 5-8.

2

P-values from two-way ANOVA. Zn × RSG interactions were not significant, P > 0.05.
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Plasma Total Cholesterol
(mmol/L)

12.0
Overall
Zn
RSG

10.0

P -values
< 0.001
< 0.001
0.002

8.0
6.0
4.0
2.0
0.0
0 Zn

0Zn + RSG

30 Zn

30Zn + RSG

Figure 4.1. Effects of dietary zinc status and rosiglitazone on plasma total
cholesterol concentration in LDL-R-/- mice.
Values are means ± SEM, n = 10-15. Zn × RSG interaction was not significant (P >
0.05).
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A
HDL

non-HDL

0.27

0 Zn
0 Zn + RSG
30 Zn
30 Zn + RSG

0.24

Absorbance at 600nm

0.21
0.18
0.15
0.12
0.09
0.06
0.03
1

6

11

16

21

26

31

Fraction Number

Figure 4.2. Effects of dietary zinc status and rosiglitazone on cholesterol distribution
in different lipoprotein fractions in LDL-R-/- mice.
A. Lipoprotein-cholesterol distribution. An equal amount (50 μL) of individual plasma
samples was applied to the FPLC column. The non-HDL includes VLDL, IDL, and
LDL. B. Area under the curve. Values are means ± SEM, n = 4. Zn × RSG interactions
were not significant (P > 0.05).
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B

Area Under the Curve

1.4
1.2

non-HDL
HDL

Overall
Zn
RSG

P-values
non-HDL HDL
< 0.001 0.793
< 0.001 0.962
0.202 0.505

1.0
0.8
0.6
0.4
0.2
0.0
0 Zn

0 Zn + RSG

Figure 4.2 (Continued)
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30 Zn

30Zn + RSG

4

Overall
Zn
RSG
Zn × RSG

LPL

mRNA Expression

P -values
LPL
CD36
0.045
0.004
0.463
0.114
0.014
0.025
*
0.011

CD36

3

2

a

1

b

b

b

0
0 Zn

0Zn + RSG

30 Zn

30Zn + RSG

Figure 4.3. Effects of dietary zinc status and rosiglitazone on LPL and CD36 gene
expression in LDL-R-/- mice.
The vertical axis represents relative units, calculated as the ratio of the copy number of
the target gene over the copy number of the endogenous control (18S rRNA and β-actin,
respectively). Values are means ± SEM, n =10-15 for LPL and 7-9 for CD36 mRNA
expression, respectively. * Zn × RSG interaction was not significant (P > 0.05).
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Chaper 5. Zinc Nutritional Status Modulates Expression of AhRResponsive P450 Enzymes in Vascular Endothelial Cells
5.1

Synopsis
Zinc has anti-inflammatory properties and is crucial for the integrity of vascular

endothelial cells, and the development and homeostasis of the cardiovascular system.
The aryl hydrocarbon receptor (AhR) which is expressed in the vascular endothelium also
plays an important role in responses to xenobiotic exposure and cardiovascular
development. We hypothesize that cellular zinc can modulate induction of AhRresponsive genes in endothelial cells. To determine if zinc deficiency can alter responses
to AhR ligands, aortic endothelial cells were exposed to the AhR ligands 3, 3’, 4, 4’tetrachlorobiphenyl (PCB77) or beta-naphthoflavone (β-NF) alone or in combination
with the membrane permeable zinc chelator TPEN, followed by measurements of the
AhR responsive cytochrome P450 enzymes CYP1A1 and 1B1. Compared to vehicletreated cells, both PCB77-induced CYP1A1 activity (EROD) and mRNA expression
were significantly reduced during zinc deficiency. In addition, PCB77 and β-NFmediated up-regulation of CYP1A1 and CYP1B1 protein expression was significantly
reduced in zinc-deficient endothelial cells. The inhibition of CYP1A1 and CYP1B1
protein expression caused by zinc deficiency was reversible by cellular zinc
supplementation. Overall, our results strongly suggest that nutrition can modulate an
environmental toxicant-induced biological outcome and that adequate levels of individual
nutrients such as zinc are necessary for induction of AhR-responsive genes in vascular
endothelial cells.

5.2

Introduction
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that

is normally found in the cytoplasm and complexed with Hsp90, XAP2, Ara9 and p23.
Upon activation, the AhR complex goes through a conformational change that exposes a
nuclear localization signal domain and triggers translocation from the cytosol to the cell
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nucleus where it forms a complex with ARNT/HIF-1β. This complex recognizes specific
enhancer domain sequences in the promoter regions of responsive genes that are known
as xenobiotic response elements (XREs). The AhR/ARNT heterodimers stimulate
transcription of Phase I and Phase II xenobiotic metabolizing enzymes. Cytochrome
P450 genes, specifically those belonging to the CYP1 family (e.g. CYP1A1/2 and
CYP1B1) are highly inducible by AhR activation, and the molecular mechanisms
involved in their regulation by AhR have been well characterized [45, 50]. Although
most of the research performed on AhR has focused on its role in the molecular,
biochemical, and toxic responses to xenobiotic ligands, recent studies have also shown
that the AhR plays a critical role in the development of various organ systems and
cardiovascular homeostasis [51]. For example, mice that lack the AhR gene have been
shown to suffer from cardiac fibrosis, hypertrophy, increased left ventricular mass,
increased expression of the cardiac hypertrophy markers β-myosin heavy chain, and βmyosin light chain 2V, and increased plasma levels of the vasoactive agents angiotensin
II and endothelin-1 [164-166]. Such findings combined with the high degree of
conservation of AhR among species suggest that, in addition to orchestrating responses to
exposure to xenobiotic ligands, the AhR plays an important role in systemic homeostasis
and development [50]. Little is known about nutritional modulation of AhR-mediated
cell signaling. The current study focuses on the micronutrient zinc, because of its
importance in regulating protein structure and cell signaling [55].
Zinc has multiple roles in maintaining the physiological conditions of the
cardiovasculature [55], and zinc may be critical in normal vascular development. For
example, zinc deficiency leads to decreased function of transcription factors associated
with cardiovascular development and homeostasis (e.g. PPARs α and γ, and GATA-4)
[26, 56]. Furthermore, a threshold activity of the zinc finger transcription factors GATA4
and GATA6 is required for gene expression in the developing cardiovascular system
[167]. There is also evidence that zinc may be critical for normal AhR signaling. For
example, both AhR and ARNT can interact with the zinc finger domain of Sp1 via their
basic HLH/PAS domains [54], and AhR can participate in induction of the zinc finger
transcription factor Slug, which, in turn, regulates cellular physiology including cell
adhesion and migration [168].
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The objectives of the experiments described below were to determine if zinc plays
a critical role in AhR function in the vascular endothelium. Our data strongly suggests
that zinc is required for induction of the AhR-responsive genes CYP1A1 and CYP1B1
upon endothelial cell exposure to xenobiotic and non-toxic AhR ligands. Alterations in
AhR function and transcription present a novel mechanism for understanding induction
of vascular diseases associated with zinc deficiency and exposure to environmental
pollutants such as AhR ligands.

5.3

Materials and Methods

Cell culture and experimental media
Endothelial cells were isolated from porcine pulmonary arteries and cultured as
previously described [75]. Cells were exposed to experimental media containing the
membrane-permeable zinc chelator N, N, N', N'-Tetrakis - (2-pyridylmethyl)
ethylenediamine (TPEN) (Sigma-Aldrich, St. Louis, MO) with or without zinc
supplementation (20 µM) and/or the AhR ligands PCB77 or β-naphthoflavone (β-NF)
(Sigma-Aldrich, St. Louis, MO) for 24 h. PCB77 was kindly provided by Dr. Larry W.
Robertson (University of Iowa). The control media were composed of culture media
containing 0.05 % of ethanol and up to 0.04 % of DMSO.
.
Measurement of CYP1A activity
Cellular cytochrome P450 1A (CYP1A) activity was measured in intact
endothelial cells grown in 48 well plates (Costar, Corning Incorporated, NY) by
ethoxyresorufin-o-deethylase (EROD) activity assay as previously described [169, 170].
7-Ethoxyresorufin was used as a CYP1A substrate. CYP1A activity indicated by the
fluorescence of resorufin generated was measured using a Cytofluor 4000 plate reader
(PE Biosystems, Foster City, CA) with excitation and emission wave lengths at 530 nm
and 590 nm, respectively.
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Measurement of CYP1A1 gene expression
Total RNA was extracted with Trizol reagent (Invitrogen, Carlsbad, CA)
according to the manufacturer’s direction. cDNA was generated using the Reverse
Transcription System (Promega, Madison, WI). Gene expression of CYP1A1 was
determined by RT-PCR. β-actin was used as an endogenous control for normalizing the
expression of CYP1A1. Specific primer sequences were synthesized by IDT
Technologies, Inc, San Jose, CA. The primers used were: CYP1A1, forward, 5'-TGGAG
AGGCA AGAGT AGTTG G-3', and reverse, 5'-GGCAC AACGG AGTAG CTCAT A3’; β-actin, forward, 5’-GGGACCTGACCGACTACCTC-3’, and reverse, 5’GGGCGATGATCTTGATCTTC-3’. Thermocyclings were performed as previously
described [169, 171]. The PCR products were separated by 1% agarose gel
electrophoresis, stained with SYBR gold (Invitrogen, Carlsbad, CA) and visualized
utilizing phosphoimaging technology (FLA-2000, Fuji, Stamford, CT).
Measurement of CYP1A1 and CYP1B1 protein expression
Cellular protein was extracted as previously described [62]. Protein extracts were
electrophoresed on 8-10% SDS-polyacrylamide gels followed by transfer to
nitrocellulose membranes. The membranes were incubated in blocking solution (5 %
non-fat milk in 1×TBST) for 1 h followed by incubation with a 1:1000 dilution of
CYP1A1 goat polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, CA) or CYP1B1
rabbit polyclonal IgG (Santa Cruz Biotechnology, Santa Cruz, CA) or a 1:4000 dilution
of β-actin rabbit polyclonal IgG (Sigma, St. Louis, MO) in blocking buffer overnight at 4
°C. β-actin was used as an endogenous control to normalize the expression of proteins of
interest. The membranes were then incubated with a mouse anti-goat or goat anti-rabbit
secondary antibody conjugated to horseradish peroxidase. Signals of the blots were
measured using the enhanced chemiluminescence (ECL) detection system (GE
Healthcare, Piscataway, NJ).
Statistical analysis
Statistical analysis was performed with SPSS 12.0 (SPSS, Inc., Chicago, IL).
Data were analyzed using one way ANOVA with post hoc comparisons of the means by
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LSD procedure. Differences were considered significant at P < 0.05. Data are presented
as means ± SEM.

5.4

Results

Zinc deficiency reduces PCB77-induced CYP1A activity and CYP1A1 mRNA
expression in vascular endothelial cells
To determine if zinc deficiency can alter induction of the AhR-responsive enzyme
CYP1A1, we first measured PCB77 induction of CYP1A1 activity by the EROD assay.
As expected, PCB77, a potent AhR agonist, significantly increased cellular CYP1A1
activity. Zinc deficiency caused by TPEN treatment did not change basal CYP1A1
activity but significantly reduced PCB77-induced CYP1A1 activity in vascular
endothelial cells (Fig. 5.1A). To determine if zinc deficiency alters CYP1A1
transcription, we measured CYP1A1 mRNA expression in endothelial cells treated with
PCB77 alone or in combination with TPEN. The PCB77-mediated up-regulation of
CYP1A1 mRNA expression was significantly reduced during zinc deficiency (Fig. 5.1B).
Zinc deficiency compromises PCB77-induced CYP1A1 and CYP1B1 protein expression
in vascular endothelial cells, which can be reversed with zinc supplementation
Western blot analysis demonstrated that the compromising effect of zinc
deficiency on AhR responsive protein expression could be reversed by zinc
supplementation. Specifically, PCB77 significantly increased the cellular protein levels
of CYP1A1 and CYP1B1, both major PCB-inducible CYP1 enzymes. TPEN treatment
alone did not affect expression of the two proteins, but co-treatment with TPEN and
PCB77 led to a significant reduction in the expression of both enzymes. However, zinc
supplementation of the TPEN-treated cell culture media reversed the reduction of
CYP1A1 and CYP1B1 observed during zinc deficiency (Fig. 5.2).
Zinc deficiency compromises β-naphthoflavone-induced CYP1A1 protein expression in
vascular endothelial cells, which can be reversed with zinc supplementation
To determine if the observations made above were specific not only to PCB77
79

exposure but also relevant to other AhR ligands, similar experiments were performed
using the non-toxic AhR agonist β-NF. Treatment with β-NF significantly induced
CYP1A1 protein expression, which was significantly reduced in TPEN-treated
endothelial cells. When zinc was added back to the cell cultures, CYP1A1 protein
induction by β-NF was completely reversible (Fig. 5.3).

5.5

Discussion
The results from the experiments described above suggest that induction of AhR

responsive genes in the endothelium is dependent on zinc availability, i.e., our data
provide evidence that zinc is required for proper induction of the AhR-CYP1 pathway.
As predicted, both toxic (PCB77) and non-toxic (β-NF) AhR ligands can markedly
induce both mRNA and protein of CYP1A1, as well as activity of CYP1A1. Induction of
the CYP1A1 gene was markedly down-regulated during zinc deficiency. This suggests
that zinc deficiency can impair enzyme function, or that zinc is critical for proper
transcriptional or translational induction of gene expression. Our data also suggest that
the dysfunction of the AhR pathway is zinc specific because we were able to reverse the
reduction in protein of CYP1A1 (and CYP1B1) by zinc supplementation of TPENtreated cells.
Zinc has a critical role in protein structure, enzyme activity and gene regulation.
Most of the genes that are zinc regulated are involved in signal transduction, responses to
stress and redox changes, growth and energy utilization [172]. Thus, zinc has a role not
only in tertiary protein structure but also in the capacity of proteins to interact with DNA,
RNA and other proteins. For protein-DNA and protein-RNA interactions, zinc is
commonly found as a zinc finger motif in transcription factors [173]. Classical zinc
fingers have also been shown to interact with RNA and DNA/RNA complexes [174].
The susceptibility of zinc fingers to zinc deprivation is not well understood. For
example, certain zinc-finger transcription factors, such as 1α, 25-dihydroxyvitamin D3
(1α, 25(OH)2D3) receptor (VDR) and retinoid X receptor (RXR), have been found to be
inactivated due to loss of zinc as a consequence of NO-induced nitrosification of the
cysteine thiols in the zinc fingers [175, 176]. Following translation, a gene is also subject
80

to zinc dependency during protein folding. For example, zinc is essential for certain
chaperones, such as heat shock protein 40 (Hsp40) [177], and Hsp40, Hsp60, and Hsp70
mRNA expression were down-regulated during zinc deficiency [172].
One possible mechanism for our observed compromising effect of zinc deficiency
on PCB77-induced CYP1A1 and CYP1B1 expression and CYP1A1 activity could have
been due to changes in AhR expression. However, western blot analysis of the AhR
protein expression did not show the same pattern of change (See Appendix, Fig. V). This
suggests that zinc deficiency may affect cell signaling downstream of AhR. Studies from
other groups also suggest that neither AhR transformation to the DNA binding form nor
the AhR DNA binding is altered by depletion of metal ions, including zinc [53, 178].
However, these studies did not measure the effects of metal depletion on AhR dependent
gene regulation, which may be a major target during zinc deficiency.
We provide evidence that induction of the AhR responsive P450 genes CYP1A1
and CYP1B1 is sensitive to cellular zinc depletion. The mechanism for inhibition of
AhR-dependent gene up-regulation during zinc deficiency could be inhibition of zincdependent AhR co-factors that are necessary for transcriptional initiation and gene
induction. One of these necessary interactions occurs with the transcription co-factor
Sp1, which binds to GC-rich regions in the promoter of responsive genes and contains
three Cys2His2 zinc fingers on its C-terminal region [179, 180]. It has been
demonstrated that Sp1 expression and function is significantly reduced by cellular
depletion of zinc and other metals [53, 181] and that CYP1A1 induction requires
AhR/ARNT interactions with Sp1 [54]. Thus Sp1 may be a critical element in
understanding the involvement of the AhR in the regulation of cardiovascular functions.
Zinc finger DNA-binding proteins such as members of the Sp1 family also
contain redox-sensitive thiol groups [182]. For example, attenuation of cardiac
dysfunction by PPAR-α agonists is associated with down-regulation of redox-regulated
transcription factors, including Sp1, NF-κB, and AP-1 [183]. The regulation of redoxregulated transcription factors by zinc and involvement of PPAR signaling further
supports our data that zinc is also required for the anti-inflammatory properties of both
PPAR-α and -γ agonists [26].
In summary, there is clear evidence that AhR function plays a critical role in the
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development and homeostasis of the cardiovascular system. Our results demonstrate that
zinc deficiency can inhibit AhR-dependent gene induction. Impairment of the AhR
pathway presents an additional molecular mechanism by which zinc deficiency
negatively alters transcription factor function and homeostasis of the vascular system.
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Figure 5.1. Zinc deficiency reduces PCB77-induced CYP1A activity and CYP1A1
mRNA expression in vascular endothelial cells.
A. CYP1A activity measured by EROD assay. Endothelial cells were exposed to vehicle
control (0.05 % of ethanol and 0.04 % of DMSO), TPEN (1.0 μM), PCB77 (0.04 μM), or
TPEN (1.0 μM) plus PCB77 (0.04 μM) for 24 hours. Bars with different letters (a, b, c)
are statistically different from each other (P < 0.05). n = 8. B. CYP1A1 mRNA
expression measured by RT-PCR. Cells were exposed to vehicle control, TPEN, PCB77
(3.4 μM), or TPEN plus PCB77 for 24 hours. The gel data are a representative of the
typical outcome of four repeated RT-PCR experiments.
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Figure 5.2. Zinc deficiency compromises PCB77-induced CYP1A1 and CYP1B1
protein expression in vascular endothelial cells
Similar to Figure 5.1, endothelial cells were exposed to vehicle control, TPEN, PCB77
(3.4 μM), TPEN plus PCB77, or TPEN with zinc supplementation (20 μM) plus PCB77
for 24 hours. The values are ratios of the densitometric units of CYP1A1 or CYP1B1
over those of β-actin. Bars with different letters (a, b, c for CYP1A1 and a’, b’, c’, d’ for
CYP1B1) are statistically different from each other (P < 0.05). n = 3. The gel data are a
representative of the typical outcome of three repeated western blot experiments.
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Figure 5.3. Zinc deficiency compromises β-naphthoflavone-induced CYP1A1
protein expression in vascular endothelial cells
Endothelial cells were exposed to vehicle control, TPEN, β- NF (1.0 μM), TPEN plus βNF, or TPEN with zinc supplementation plus β- NF for 24 hours. The values are ratios
of the densitometric units of CYP1A1 over those of β-actin. Bars with different letters
(a, b, c) are statistically different from each other (P < 0.05). n = 3. The gel data are a
representative of the typical outcome of three repeated western blot experiments.
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Chaper 6. Conclusion

Atherosclerosis is a major health issue in developed countries and has an
increasing incidence in developing countries as well. The pathogenesis of atherosclerosis
is thought to begin with endothelial cell dysfunction. Through increased expression of
adhesion molecules, activated endothelial cells mediate monocyte attachment and
migration through the endothelium into the arterial wall, where the monocytes
differentiate into macrophages and by taking up modified lipids further become foam
cells. In more advanced stages of atherosclerosis, formation of fibrous plaques and
complex lesions will ensue, leading to an acute clinical event by plaque rupture and
thrombosis [1, 2]. The development of atherosclerosis is influenced by both genetic and
environmental risk factors with the later including nutritional risk factors [1, 2].
Deficiency of the micronutrient zinc can constitute a risk factor for atherosclerosis [3, 4].
Since the initial and early stages of atherosclerosis are the time points when nutrition (e.g.
zinc) modulation could have the most efficient effects, the research described in this
dissertation focuses on early events of atherosclerosis, including endothelial cell
activation in the in vitro studies and a more systemic profile of early events of
atherosclerosis in the in vivo studies.
One major link of the four chapters of this dissertation is the micronutrient zinc.
In the current studies, the cells were made zinc deficient by treatment with the zinc
chelators TPEN or DTPA. TPEN is a membrane permeable zinc-specific chelator that
decreases intracellular zinc concentrations by depleting zinc from both a cytoplasmic free
zinc pool and a nuclear pool [184-186]. The chelation of cations other than zinc by
TPEN is very low with the affinities of metal to TPEN: Zn2+ > Fe2+ > Mn2+ >> Ca2+ =
Mg2+ [187]. In a previous study of our lab, cultured endothelial cells pre-treated with
TPEN (2 μM) for 24 h were labeled with Zinquin ethyl ester, and the fluorescence that
reflects biologically available labile zinc was measured, demonstrating that cellular labile
zinc deficiency can be induced by exposure of endothelial cells to TPEN for 24 h [25].
In the current in vitro study, the same duration of TPEN treatment (i.e. 24 h) but lower
concentrations of TPEN (1.0 or 1.5 μM) were applied because 2 μM of TPEN would
cause massive cell death in the vascular endothelial cell cultures at the treatment time
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point of 24 h. Therefore, the highest non-toxic concentrations of TPEN were chosen to
perform these experiments on the endothelial cells. Based on the observed biological
effects caused by zinc chelation and supplementation as described in Chapter Two, the
TPEN treatment should have reduced the intracellular labile zinc. DTPA is a membrane
impermeable chelator that decreases extracellular zinc concentrations [184]. DTPA is a
potent chelator of zinc, but is not only specific for zinc [188]. A previous study has
shown that in spite of the detrimental effect of DTPA on thymidine incorporation in 3T3
cells, it did not decrease the measurable cellular total zinc concentration, which may be
the result of a decreased zinc concentration of only a small compartment of the cell,
possibly the plasma membrane, that caused too small a change to be detected by total zinc
analysis [188]. In the transient transfection-luciferase assay described in Chapter Two,
the compromising effect of DTPA-induced zinc deficiency on the transactivation activity
of PPARγ was obvious despite the fact that the cellular zinc concentrations in RAVSMC
were not measured. Nevertheless, one major deficiency of the present in vitro study is
the lack of determination of the intracellular zinc concentrations. There are several ways
to measure cellular zinc, with the most commonly used one being atomic absorption
spectrometry, which measures total cellular zinc [189]. Fluorescence microscopy with
the zinc-specific fluorescent probe FluoZin-3 can be used to quantify cellular labile zinc
[190]. Recently, flow cytometry with FluoZin-3 has been employed to measure the
concentrations of biologically active labile zinc in both a single cell and distinct cell
populations [189]. Unlike the fluorescent probe Zinquin that was used in Hennig’s
laboratory before to determine intracellular labile zinc, the FluoZin-3 does not seem to
interact with zinc that is bound to proteins like metallothionein [189], therefore, this
method has the advantage of measuring labile zinc more accurately. Another novel way
to measure intracellular exchangeable zinc is by using a fluorescence resonance energy
transfer (FRET) based ratiometric zinc sensor to image and quantify zinc levels in resting
eukaryotic cells [191]. In future in vitro zinc studies, it is important that the
concentrations of intracellular labile zinc be routinely quantified using either the flow
cytometric method or the ratiometric imaging method mentioned above, so that the
observed biological effects caused by different cellular zinc status can be properly
explained.
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In the current in vivo study, the LDL-R-/- mice were made mildly zinc deficient by
feeding zinc-deficient diets that contained 0.4 mg/kg (not 0 mg/kg) of zinc for a relatively
short period. Because zinc is such an important micronutrient involved in multiple life
processes, it is important not to completely deplete zinc in these diets. The small amount
of zinc in the zinc-deficient diets helped to keep the animals from significant weight loss,
which could otherwise constitute a confounding factor in the study. It was still somewhat
unexpected that the LDL-R-/- mice on the zinc-deficient diets did not gain any weight
(Fig. 3.2). Our previous feeding study applying the same type of diets on wild type (WT)
mice showed that the zinc-deficient WT mice gained less weight than the zinc-adequate
WT mice. The failure of the zinc-deficient LDL-R-/- mice to gain weight in the current in
vivo study suggests that this strain of mouse is more sensitive to zinc-depleted diets
compared to the WT mice. Furthermore, our preliminary studies showed that the zincdeficient mice always decreased their food intake compared to the zinc-adequate mice,
which could partially explain their different patterns of body weight change. Some of the
biological effects observed in the current in vivo study could be associated with the
different food intake and weight change in the zinc-deficient vs. the zinc-adequate mice.
In addition, the plasma zinc concentrations did not reflect the dietary zinc intake in our
study. Plasma zinc concentration is not always a good indicator of body zinc levels. For
example, while plasma zinc was found to be normal in elderly patients with mild zinc
deficiency, the zinc levels in granulocytes and lymphocytes were decreased compared to
the younger control subjects [192]. Zinc redistribution is a well recognized phenomenon
during acute-phase response to injury or infection, when zinc moves into the liver with
reduced plasma zinc concentration [193]. Zinc redistribution also can exist between
plasma and peripheral blood mononuclear cells [194]. Determination of labile zinc in
leukocytes instead of plasma zinc may be a more precise way of indicating the body zinc
level, and it also allows for the correlation of leukocyte zinc levels with immunological
effects [189]. The length of the in vivo study was based on our previous research using
the same animal model and a similar dietary regimen, which has demonstrated that zinc
deficiency for four weeks is sufficient to increase plasma lipids and atherosclerotic
markers [118]. A longer-term study may reveal a more robust outcome revealing the proatherogenic effects of zinc deficiency and the anti-atherogenic properties of rosiglitazone,
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and the interactions between zinc status and rosiglitazone in regulating the development
of atherosclerosis as well.
Oxidative stress links all the main signaling pathways studied in this dissertation,
i.e. NF-κB, AhR, and PPAR. Oxidative stress plays a central role in atherosclerosis.
ROS, the main source of oxidative stress, have a dual role in the vasculature. ROS
function as homeostatic signaling molecules that regulate cell growth and adaptation
responses at physiological concentrations, however, they can cause cellular injury and
death at higher concentrations. The pathogenesis of atherosclerosis involves an
imbalance between oxidative stress and antioxidant defense (including anti-oxidant
enzymes and endogenous /exogenous anti-oxidants) that causes excessive ROS
production [195]. Either inadequate or excessive cellular zinc can induce oxidative
stress by altering the expression and activity of anti-oxidant enzymes and/or increasing
ROS production. In the current study, zinc deficiency caused by TPEN chelation
increased ROS generation in vascular endothelial cells (Fig. 2.1). In this experiment
however, zinc supplementation to the chelator containing media only partially rescued the
zinc-deficiency-induced cellular oxidative stress, and surprisingly, zinc supplementation
alone also induced cellular oxidative stress in endothelial cells (Fig. 2.1). These
observations were not in consistency with either the NF-κB DNA binding activity data
(Fig. 2.2) or the COX-2 and E-selectin mRNA expression data (Fig. 2.3). This could be
due to the limitations of the DCF fluorescence method used for cellular oxidative stress
measurement. The DCF assay is sensitive to ONOO–, H2O2, and •OH, but not to NO,
hypochlorous acid (HOCl) or O2• – [196], therefore could not have reflected the whole
cellular oxidative stress profile in the endothelial cells. In order to determine cellular
oxidative stress more accurately, future studies should combine the DCF assay with
several other methods, such as the luminol- and lucigenin-amplified chemiluminescence
assays which are sensitive to HOCl and O2• –, respectively [196].
Being a redox-sensitive transcription factor, NF-κB can be activated by oxidative
stress [85]. Activation of NF-κB leads to up-regulation of downstream target genes, such
as TNFα, and COX-2 [88, 119]. Expression of these inflammatory mediators can further
increase cellular oxidative stress by generating ROS [44]. This positive feedback loop
amplifies the oxidative stress signaling. Activation of the AhR by certain ligands such as
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2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) can also lead to oxidative stress responses
through induction of inflammatory mediators like TNFα and COX-2, modulation of
antioxidant and prooxidant enzymes such as SOD and XO/XDH, and induction of
cytochrome P450 [44]. Oxidative stress can also activate PPAR[197], which has antiinflammatory properties and would reduce oxidative stress [198-200] and/or prevent
oxidative stress induced deleterious effects [201, 202]. Cellular oxidative stress thus
cross-talks with multiple signaling pathways, resulting in synergism or antagonism
among signaling pathways that depend on the overall oxidative stress/antioxidant balance
within a cell (Fig. 6.1).
Crosstalk between the transcription factors NF-κB, PPAR, and AhR as influenced
by zinc nutritional status also helps to integrate the studies described in this dissertation
(Fig. 6.1). There is a bidirectional antagonism between the NF-κB and PPAR signaling
pathways. PPAR can repress the NF-κB pathway by physically interacting with the p50
and p65 subunits of NF-κB, and by inducing the expression of IκB, the major inhibitor of
NF-κB [21]. On the other hand, NF-κB activation can negatively regulate PPAR
signaling by down-regulating the expression of PPAR mRNAs and inhibiting the
transcriptional activity of PPAR proteins [203]. The interaction between PPAR and NFκB provides an efficient way of regulating multiple cellular events. In the current study,
zinc deficiency activates the NF-κB pathway possibly by increasing cellular oxidative
stress, meanwhile, it suppresses the PPAR pathway by inhibiting PPAR expression and
the transactivational activity of the PPAR proteins. When cells are zinc deficient, the
activation of NF-κB can further inhibit PPAR function and the suppressed PPAR
signaling can contribute to further activation of the NF-κB and associated downstream
inflammatory events.
Similarly, physical interaction and mutual functional repression also exist
between the NF-κB and AhR signaling pathways. NF-κB activation can inhibit AhR
dependent gene expression; conversely, ligand activation of AhR can also suppress
transcriptional activation by NF-κB [204, 205]. The mutual repression is mediated by the
physical interaction between the p65 subunit of NF-κB and AhR, and may also involve
the roles of nuclear receptor coactivators p300/CBP and steroid receptor coactivator-1
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(SRC-1). Since both p300/CBP and SRC-1 serve as common coactivators of NF-κB and
AhR for maximum transcriptional activation, a competition for coactivator binding is
possible, which will lead to activation of one pathway and repression of the other
pathway [204-206]. In the present study, zinc deficiency might impair the AhR pathway
either directly by affecting the AhR translocation, cofactor recruitment, and/or AhR-XRE
binding, or indirectly by activating the NF-κB pathway. Likewise, during zinc deficiency
the activation of NF-κB can further inhibit the AhR function and the compromised AhR
signaling can intensify the activation of NF-κB and inflammation, eventually
contributing to the pathology of atherosclerosis.
One common finding in both the in vitro and the in vivo studies described in this
dissertation is the requirement of adequate zinc for proper PPAR function. Since there
are so many zinc-finger containing proteins, it is possible that zinc deficiency can also
alter functions of some other zinc-finger transcription factors in addition to PPAR.
However, my data demonstrate that zinc deficiency decreases the protein expression of
PPARα (Fig. 2.5B) but not of estrogen receptor (ER)α (see Appendix, Fig. VI), another
zinc-finger transcription factor, in vascular endothelial cells. This observation suggests
some specificity of zinc deficiency for altering PPAR function, findings which are also
supported by the reversibility studies with zinc supplementation.
An interesting finding described in this dissertation is that zinc deficiency seems
to protect against PCB77-induced inflammation in endothelial cells. Since both PCB77
[169] and zinc deficiency increases cellular oxidative stress, we initially thought that zinc
deficiency could amplify PCB77-induced inflammatory responses. However, the current
data showed the opposite. Specifically, PCB77-incuced CYP1A1 activity and expression
(Fig. 5.1, 5.2), and up-regulation of adhesion molecules, such as vascular cell adhesion
molecule-1 (VCAM-1) and E-selectin (see Appendix, Fig. VII), were all compromised
during zinc-deficiency. Since the PCB 77-induced endothelial cell inflammatory
responses are mediated through the AhR-CYP1A pathway [62], one could anticipate that
zinc ion could be required for some upstream events of the whole pathway, such as
activation of the AhR-CYP1A1 pathway. In other words, during zinc deficiency, the
AhR-CYP1A1 activation gets inhibited, leading to inactivation of the downstream
inflammatory responses as a consequence. The inhibitory effect of zinc deficiency on the
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non-toxic AhR ligand β-NF-induced CYP1A1 expression (Fig. 5.3) was supportive of
this point.
The findings described in this dissertation foster a number of important questions
that could be addressed in future studies. For example, the hitherto poorly understood
upstream events in zinc deficiency-induced endothelial cell activation need to be
clarified. The relevant questions include, but are not limited to, 1) how does zinc
deficiency induce oxidative stress in endothelial cells and which signaling pathways are
involved, and 2) how does the increased oxidative stress activate NF-κB in endothelial
cells and which kinases are involved. Another question is the detailed mechanisms
involved in zinc deficiency-induced inhibition of the AhR-CYP1 pathway in vascular
endothelial cells. In this aspect, future studies may address whether the translocation of
AhR and/or ARNT, the coactivator recruitment, the AhR-XRE binding, and/or the
transactivation activity of AhR are influenced by zinc deficiency in these cells.
In conclusion, zinc nutrition can affect the pathology of inflammatory diseases
such as atherosclerosis. Zinc deficiency by itself constitutes a risk factor of
atherosclerosis. In addition, zinc deficiency can modify the biological outcomes of other
risk factors of atherosclerosis such as coplanar PCBs, and of certain medicines such as
TZDs. The study described in this dissertation shows that zinc deficiency can intensify
inflammatory events in vascular endothelial cells and the whole animal as well. The
mechanisms involved include inhibition of the anti-inflammatory signaling pathways,
such as the PPAR, and activation of the pro-inflammatory pathways, such as the NF-κB,
during zinc deficiency (Fig. 6.1).
In general, data presented in this dissertation are novel and important for
population groups at risk of zinc deficiency and exposure to environmental pollutants
such as PCBs, and patients receiving therapy with TZDs. The results shown also
emphasize the importance of the micronutrient zinc in prevention of atherosclerosis and
the importance of adequate dietary zinc in humans during treatment phases associated
with diabetes and other cardiovascular risk factors.
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Figure 6.1. Crosstalk between the NF-κB, PPAR, and AhR pathways during zinc
deficiency.
Zinc deficiency induces oxidative stress, which activates the NF-κB signaling pathway
that leads to inflammation and atherosclerosis. Meanwhile, zinc deficiency inhibits both
PPAR and AhR signaling, blocking their inhibitory effects on NF-κB and further
contributing to activation of NF-κB and inflammation. Activation of NF-κB can
intensify the oxidative stress signaling by generating more ROS, and is able to inhibit
both PPAR and AhR pathways as well. AhR activation can be pro-inflammatory by
generating oxidative stress while activation of the anti-inflammatory PPAR can generally
prevent the deleterious effects caused by oxidative stress.

Copyright © Huiyun Shen 2008
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Appendix

Methods
1. Primary endothelial cell culture


Establishing primary cell culture
Endothelial cells were isolated from porcine pulmonary arteries by Dr. Bernhard
Hennig at the Molecular and Cell Nutrition Laboratory, College of Agriculture,
University of Kentucky, and subcultured in M-199 (Invitrogen Corporation,
Carlsbad, CA) containing 10% (v/v) FBS (HyClone, Logan, UT).



Freezing cells
1) Take one T75 cell culture flask with confluent endothelial cells. Rinse the
cells with 10 mL of Hanks and then add 1 mL of trypsin (0.05 %). Place the
flask in a CO2 incubator (37 °C, 5 % CO2) to facilitate trypsin digestion.
2) When the cells are detached from the bottom of the flask, add 10 mL of
M199/10 % FBS, suspend the cells by repeated pipetting, and transfer the cell
suspension into a 15 mL conical tube followed by centrifugation at 1,200 rpm
at 37 °C for 10 min.
3) Gently decant supernatant, add 2 mL of freshly made freezing cocktail
(M199/20 % FBS, 7 % DMSO) to resuspend the cells and transfer the cell
suspension to two cryovials with 1 mL per vial. Label the cryovials with
passage, date, and operator, and keep them at -20 °C for 1 h and then at -80 °C
overnight. The cryovials are transferred to liquid nitrogen the next day for
longtime storage.



Reviving cells
1) Find one cryovial containing 1 mL of frozen endothelial cell suspension.
2) Add 0.5 mL of M199/10 % FBS (pre-warmed to 37 °C) to the cryovial,
pipette repeatedly and keep transferring the thawed cells into a 15 mL conical
tube.
3) After all cells are suspended in the 15 mL tube, centrifuge at 1,200 rpm for 10
min at 37 °C.
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4) Gently decant supernatant, and resuspend the cells in 10 mL of M199/10 %
FBS, centrifuge at 1,200 rpm for 10 min at 37 °C. Repeat this step one more
time.
5) Gently decant supernatant, resuspend the cells in 15 mL of M199/10 % FBS
and transfer the cell suspension to a T75 flask. Place the flask in a CO2
incubator.
6) Change the media 3 ~ 4 h later when the cells should have attached to the
bottom of the flask.
7) Change the media again the next day, and wait for two days until the cells are
confluent.
2. Cellular oxidative stress measurement
1) Take one T-75 culture flask, after trypsin digestion add 60 mL of M199/10 %
FBS. Distribute 0.8 mL of the endothelial cell suspension into each well of a
24 well plate.
2) Incubate the cells for 48 h in CO2 incubator, then synchronize the cells (about
90 % confluent) in M199/0 % FBS overnight followed by treatment in
M199/1 % FBS for 24 h.
3) Rinse the cells twice with HEPES buffered salt solution (HBSS) * (25 mM
HEPES, 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 25 mM NaHCO3, 15
mM glucose, pH 7.4) and incubate with 0.5 mL of HBSS containing 10 μM of
2’,7’-dichlorodihydrofluorescein diacetate (H2DCF-DA)** at 37 °C for 30 min
at dark.
4) Wash the cells twice with HBSS and replace with 0.5 mL of HBSS.
5) Measure the DCF fluorescence using a fluorescence microplate reader with
excitation and emission wavelengths of 485 nm and 530 nm, respectively.
*

To make 100 mL of HBSS: dissolve 0.6g HEPES, 0.7g NaCl, 40 mg KCl, 26.5

mg CaCl2, 0.21g NaHCO3, and 0.27g glucose in distilled H2O, adjust pH 7.4 with
NaOH, and then sterilize by filtering.
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**

H2DCF-DA is added from a stock solution (10 mM): dissolve 2 mg H2DCF-DA

in 0.4 mL EtOH, store at -80 °C at dark.
3. RNA isolation


RNA isolation from endothelial cells
Total RNA was isolated from endothelial cells using TRIzol Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruction.



RNA isolation from mouse aorta
Total RNA was isolated from mouse aorta using RNeasy Fibrous Tissue Mini Kit
(Qiagen, Valencia, CA) according to the manufacturer’s instruction.



RNA isolation from mouse liver
Total RNA was isolated from mouse liver using RNeasy Mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instruction.

4. Measurement of RNA concentration
1) Add 3 μL of RNA sample into 600 μL of RNase-free H2O. Mix by repeated
pipetting.
2) Measure RNA concentration and A260/A280 value using a SmartSpec 3000
Spectrophotometer (Bio-Rad, Hercules, CA).
5. Reverse transcription (RT) reaction
1) Dilute 1 μg of RNA in RNase-free H2O to 9.9 μL. Heat the RNA at 70 °C for
10 min in a MJ Mini 48-Well Personal Thermal Cycler (Bio-Rad, Hercules,
CA) and put on ice.
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2) Make a Master Mix using the Reverse Transcription System (Promega,
Madison, WI):
MgCl2 (25 mM):

4.0 μL

Reverse Transcription 10 × Buffer:

2.0 μL

dNTP Mix (10 mM):

2.0 μL

RNasin Ribonuclease Inhibitor (40 u/μL):

0.5 μL

Random Primers (500 μg/mL):

1.0 μL

AMV Reverse Transcriptase (10 u/μL):

0.6 μL
10.1 μL

Total volume

3) Add 9.9 μL of the RNA into 10.1 μL of the Master Mix and mix well.
4) RT reaction in the MJ Mini 48-Well Personal Thermal Cycler: 25 °C for 10
min → 42 °C for 60 min → 95 °C for 5 min → 4 °C for 5 min.
5) Store the cDNA at -20 °C.
6. Polymerase chain reaction (PCR)
1) Prepare the PCR reaction mixture using Taq PCR Master Mix Kit (Qiagen,
Valencia, CA)
10.5 μL

Distilled H2O:
Target gene sense (20 pM):

0.5 μL

Target gene antisense (20 pM):

0.5 μL

cDNA:

1.0 μL

Taq PCR Master Mix*:

12.5 μL

Total volume

25.0 μL

* containing 49 u/mL of Taq DNA Polymerase
2) Run PCR reaction in the MJ Mini 48-Well Personal Thermal Cycler
•

PCR programs for target genes:

COX-2
95 °C for 5 min, 1 cycle;
95 °C for 30 sec → 52.3 °C for 30 sec → 72 °C for 30 sec, 26 cycles;
72 °C for 7 min, 1 cycle.
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E-selectin
94 °C for 5 min, 1 cycle;
94 °C for 1 min → 58.6 °C for 1 min → 72 °C for 1 min, 22 cycles;
72 °C for 7 min, 1 cycle.
CYP1A1
94 °C for 4 min, 1 cycle;
94 °C for 1 min → 58 °C for 1 min → 72 °C for 1 min, 29 cycles;
72 °C for 7 min, 1 cycle.

β-actin
94 °C for 4 min, 1 cycle;
94 °C for 1 min → 53 °C for 1 min → 72 °C for 1 min, 21 cycles;
72 °C for 7 min, 1 cycle.
7. Real-time PCR
The real-time PCR reactions were performed using the ABI Prism 7300 Real
Time PCR System (Applied Biosystems, Branchburg, NJ). The quantification of
PCR products was based on standard curves for the target gene and for the
endogenous control, respectively. A serial dilution of cDNA was made to
establish the standard curve by assigning artificial numbers (e.g. 160, 80, 40, and
20) of mRNA copy to each standard reaction.


CYBR Green gene expression assay for porcine PPARα
1) Prepare the real-time PCR reaction mixtures:
Nuclease-free H2O (Ambion, Austin, TX):

7.5 μL

PPARα / β-actin forward (100 μM):

1.5 μL

PPARα / β-actin reverse (100 μM):

1.5 μL

CYBR Green PCR Master Mix (Applied Biosystems, 2×):

12.5 μL
2.0 μL

cDNA:

25.0 μL

Total volume
2) Real-time PCR:
95 °C for 10 min, 1 cycle;
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95 °C for 15 sec → 60 °C for 1 min, 40 cycles.


TaqMan gene expression assays for mouse PPARγ, iNOS, MCP-1, CD36, and
LPL
1) Prepare the real-time PCR reaction mixtures:
Nuclease-free H2O (Ambion, Austin, TX):

9.25 μL

Probe and Primers Mix* (Applied Biosystems, 20×):

1.25 μL

TaqMan Universal PCR Master Mix, No AmpErase UNG (AB, 2×): 12.5 μL
2.0 μL

cDNA:

25.0 μL

Total volume
2) Real-time PCR:
95 °C for 10 min, 1 cycle;
95 °C for 15 sec → 60 °C for 1 min, 40 cycles.

* The Probe and Primers Mixes were purchased from Applied Biosystems as
TaqMan Gene Expression Assays pre-designed for different genes, i.e., mouse
PPARγ, iNOS, MCP-1, CD36, and LPL. Endogenous controls used were either
Eukaryotic 18S rRNA or mouse ACTB, both of which are pre-developed TaqMan
Assay reagents purchased from Applied Biosystems.
8. Cellular protein extraction


Cellular protein extraction from endothelial cells*
1) Rinse the endothelial monolayer twice with 5 mL of ice-cold PBS.
2) Add 3 mL of PBS and scrape the cells into a 15 mL conical tube.
3) Rinse dish with 3 mL of PBS and transfer into the same tube.
4) Centrifuge at 2,500 rpm for 10 min at 4 °C.
5) Decant the supernatant and resuspend the cells in 5 mL of PBS.
6) Centrifuge at 2,500 rpm for 5 min at 4 °C.
7) Carefully remove the supernatant and add 100 μL of Lysis Buffer ** [20 mM
Tris-HCl (pH 7.4), 150 mM NaCl, 0.5 % (v/v) Triton X-100, 1 mM EDTA,
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0.05 % (w/v) NP-40, 0.1 mg/mL PMSF, 1 mM Na3VO4, 2.5 μg/mL leupeptin,
and 10 μg/mL pepstatin].
8) Vortex for 30 sec then put on ice for 2 min, repeat this step for 6 ~ 8 times.
9) Incubate on ice for 30 ~ 60 min.
10) Vortex and then centrifuge at 13,000 rpm for 15 min at 4 °C.
11) Take the supernatant and make aliquots of it, quick freeze the aliquots on dry
ice and store at -80 °C.
* All steps were carried out at 4 °C or on ice.
** Make Lysis Buffer (-) then add NP-40, PMSF, Na3VO4, leupeptin, and
pepstatin before using:
i) To make 100 mL of Lysis Buffer (-): 2 mL Tris-HCl (1 M, pH 7.4) + 15 mL
NaCl (1 M) + 5 mL Triton X-100 (10 %, v/v) + 1 mL EDTA (0.1M) + 73.75 mL
distilled H2O.
ii) To make 1 mL of Lysis Buffer: 975 μL Lysis Buffer (-) + 5 μL NP-40 (10 %
w/v) + 10 μL PMSF (10 mg/mL) + 5 μL Na3VO4 (200 mM) + 5 μL Protease
Inhibitor Cocktail (0.5 mg/mL leupeptin, 2 mg/mL pepstatin).


Cellular protein extraction from liver tissue
1) Thaw the Lysis Buffer* [50 mM Tris, 150 mM NaCl, 0.05 % (v/v) Triton X100, 0.1 mg/mL PMSF, 1 mM Na3VO4, 0.05 % (w/v) NP-40, 1 mM EDTA, 1
mM EGTA, 2.5 μg/mL leupeptin, 10 μg/mL pepstatin A, 10 μg/mL aprotinin,
and 2 mM DTT, pH 7.4] aliquot at 37 °C and add 50 μL/sample into a glass
homogenization tube on ice.
2) Cut frozen liver tissue on ice into approximately 2 mm3 pieces with scalpel
and submerge into Lysis Buffer in the homogenizing tube immediately.
3) Homogenize for 10 sec on ice and let stand for 30 min on ice.
4) Transfer the homogenate into an eppendorf tube and centrifuge at 14,000 rpm
for 30 min at 4 °C.
5) Obtain the supernatant, vortex for 5 sec, make aliquots, quick freeze the
aliquots on dry ice, and store at -80 °C.
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* To make 100 mL of Lysis Buffer: 75 mL Tris (67mM)-NaCl (200 mM) (pH
7.4) + 0.5 mL Triton X-100 (10 %, v/v) + 1 mL PMSF (10 mg/mL) + 0.5 mL
Na3VO4 (200 mM) + 0.5 mL NP-40 (10 %, w/v) + 1 mL EDTA (100 mM) + 1 mL
EGTA (100 mM) + 0.25 mL leupeptin (1 mg/mL) + 1 mL pepstatin A (1 mg/mL)
+ 0.1 mL aprotinin (10 mg/mL) + 2 mL DTT (100 mM) + 17.15 mL distilled
H2O.
9. Measurement of protein extract concentration
Protein concentrations were measured spectrophotometrically by Bradford Assay.
1) Prepare a series of protein standard, for example, 0, 2, 4, 6, 8, and 10 μg/mL
of bovine serum albumin (BSA) using the Quick Start Bradford Protein Assay
Kit (Bio-Rad, Hercules, CA).
2) Dilute each protein sample by 500 fold, i.e., 2 μL of sample + 998 μL of
Bradford Dye Reagent, mix and let stand for 5 min at room temperature.
3) Measure A595 using a UV-1700PC spectrophotometer (Shimadzu Scientific
Instruments, Columbia, MD) and get the protein concentrations.
10. Western blot


Preparing samples
1) Dilute protein samples with distilled H2O to 20 μL with the total amount of
protein 20 ~ 25 μg each.
2) Add 5 μL of 5× Sample Loading Buffer* each.
3) Boil the samples at 95 ~100 °C for 5 ~7 min.
4) Put the samples on ice until loading.
* To make 8 mL of 5× Sample Loading Buffer: 1 mL 0.5 M Tris-HCl (pH 6.8) +
0.8 mL 60 % glycerol + 1.6 mL 10 % SDS + 0.4 mL 2-mercaptoethanol + 0.4 mL
1 % (w/v) bromophenol blue + 3.8 mL distilled H2O, make aliquots and store at 80 °C.



Preparing the gel
1) Separating/Resolving gel: lower gel (Table I).
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2) Stacking gel: upper gel (Table I).
Table I. Preparation of SDS-PAGE gels
Stacking gel

Separating gel

Separating gel

5%

8%

10 %

Distilled H2O

6.09 mL

5.34 mL

4.84 mL

0.5 M Tris-HCl (pH 6.8)

2.5 mL

-

-

1.5 M Tris-HCl (pH 8.8)

-

2.5 mL

2.5 mL

40 % Acrylamide/bis

1.25 mL

2 mL

2.5 mL

10 % SDS

100 μL

100 μL

100 μL

10 % APS

50 μL

50 μL

50 μL

TEMED

10 μL

10 μL

10 μL

Total volume

10 mL

10 mL

10 mL



Running the gel
1) Prepare the Running Buffer*
2) Put the gel in and load the samples and the protein marker (Bio-Rad,
Hercules, CA).
3) Run at 100 V until the bromophenol blue reaches the bottom of the separating
gel.
* To make 600 mL of 10 × Running Buffer: dissolve 18 g of Tris Base, 86.4 g of
glycine, and 6 g of SDS in distilled H2O. To run the gel, dilute the 10 × Running
Buffer into 1× Running Buffer with distilled H2O.



Transfer onto nitrocellulose membrane
1) Prepare the Transfer Buffer**
2) Make the “transfer sandwich” in ice-cold Transfer Buffer: from cathode to
anode, place sponge, filter paper, gel, nitrocellulose membrane, filter paper,
and sponge in turn. Close, properly put in apparatus.
3) Add Transfer buffer, put in ice box and cover the whole thing with ice.
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4) Run at 350 mA for 2h.
** To make 800 mL of Transfer Buffer: 80 mL 10 × Running Buffer + 160 mL
methanol + 560 mL distilled H2O, cover with parafilm and leave at -20 °C for 1 h
before use.


Blocking
Block the membrane by gentle shaking in the Blocking Buffer [5 % non-fat milk
in 1×TBST *** (50 mM Tris Base, 150 mM NaCl, 0.05 % Tween 20)] for 1h at
room temperature.
*** To make 1L of 10 × TBS: dissolve 60.5 g Tris Base and 87.6 g NaCl in
distilled H2O, adjust pH to 7.5 with HCl, bring volume to 1L. Dilute 100 mL 10
× TBS with 900 mL distilled H2O to get 1L 1 × TBS. To make 500 mL 1×TBST:
500 mL 1 × TBS + 250 μL Tween 20.



Binding of the primary antibody
1) Add certain amount of the primary antibody into the Blocking Buffer (e.g.
1:1000 for COX-2, CYP1A1, and .1: 4000 for β-actin).
2) Submerge the membrane in the buffer and gently shake overnight at 4 °C.
3) Wash the membrane with the Blocking Buffer for 5 min, repeat 3 times.



Binding of the secondary antibody
1) Add certain amount of the secondary antibody into the Blocking Buffer
(usually a 1:3000 dilution).
2) Submerge the membrane in the buffer and gently shake for 1h 15 min at room
temperature.
3) Wash the membrane with 1×TBST for 5 min, repeat 5 times.



Visualization
1) Discard the TBST.
2) Mix enhanced chemiluminescence (ECL) reagents (GE Healthcare,
Piscataway, NJ): 1.5 mL reagent A + 1.5 mL reagent B.
3) Distribute the mixture evenly by pipette on the membrane. Let sit for 1 min.
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4) Dry the membrane gently on a Kimwipe and put the membrane into the plastic
case in the cassette.
5) Put in a piece of Blue Basic Autorad Film (ISC BioExpress, Kaysville, UT)
and expose it for 1 ~ 15 min depending on the amount of target protein on the
membrane.
6) Develop the film.
11. Nuclear protein extraction


Nuclear protein extraction from endothelial cells*
1) Rinse the endothelial monolayer twice with 5 mL of ice-cold PBS.
2) Add 3 mL of PBS and scrape the cells into a 15 mL conical tube.
3) Rinse dish with 3 mL of PBS and transfer into the same tube.
4) Centrifuge at 2,500 rpm for 10 min at 4 °C.
5) Resuspend the cells in 400 μL of buffer A [10 mM HEPES (pH 7.9), 10 mM
KCl, 0.1 mM EDTA, 1 mM DTT, and 0.5 mM PMSF]. Incubate on ice for 15
min.
6) Add 25 μL of 10 % NP-40, mix, incubate on ice for about 5 min until 90 ~ 95
% of the cells were lysed.
7) Centrifuge at 14,000 rpm for 3 min at 4 °C.
8) Gently remove the supernatant and resuspend the nuclear pellet in 20 ~50 μL
of buffer B [20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM DTT,
and 1 mM PMSF] according to the cell number.
9) Lyse the nuclei by shaking vigorously for 5 min at 4 °C.
10) Centrifuge at 14,000 rpm for 10 min at 4 °C.
11) Collect the supernatant, make aliquots, quick freeze the aliquots on dry ice,
and store at -80 °C.
* All steps were carried out at 4 °C or on ice.



Nuclear protein extraction from mouse liver
Nuclear proteins were extracted using CelLytic NuCLEAR Extraction Kit
(Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instruction.
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12. Electrophoretic mobility shift assay (EMSA)
EMSA assays were performed using LightShift® Chemiluminescent EMSA Kit
(PIERCE, Rockford, IL) according to the manufacturer’s instruction.
The supershift reaction mixtures contain 10 μL of antibodies specific for either
PPARα or ΝF-κB p65 subunit.
13. Zinc quantification in plasma, liver, and rosiglitazone solution
Zinc concentrations in plasma, liver, and rosiglitazone solution were analyzed by
ICP mass spectrometry by Dr. Thomas Mawhinney at the Agricultural
Experiment Station Chemical Laboratories, University of Missouri.
14. Measurement of plasma cytokines/chemokines concentrations
Concentrations of plasma IL-1α, IL-2, IL-4, IL-6, IL-10, IL-12, IL-13, IL-17,
TNFα, and MCP-1 were measured using Mouse Cytokine/Chemokine
LINCOplex kit (LINKO Research Inc., St. Louis, MO) according to the
manufacturer’s instruction. Signal detection and data analysis using Luminex 100
(Luminex Corporation, Austin, TX) and Multiplex Data Analysis Software 1.0
(Upstate USA, Inc., Chicago, IL) were performed by Jason Stevens at the Center
for Oral Health Research, University of Kentucky.
15. Measurement of plasma cholesterol concentrations
Plasma total cholesterol content was measured using Wako Cholesterol E
Enzymatic Kit (Wako Chemicals USA, Inc., Richmond, VA) according to the
manufacturer’s instruction.
.
16. Fast-performance liquid chromatography (FPLC)
Plasma cholesterol distribution in different lipoprotein fractions was measured
using FPLC by Jessica Moorleghen at the Cardiovascular Research Center,
University of Kentucky.
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17. Analysis of plasma fatty acids
1) Prepare butylated hydroxytoluene* (BHT, 100 μg/mL) in Folch Extraction
Mixture (chloroform: methanol = 2:1):
* To make 420 mL of BHT (100 μg/mL): 280 mL of chloroform + 140 mL of
methanol + 42 mg of BHT.
2) Prepare Standard [heptadecanoic acid (17:0, 5 mg/mL)]: dissolve 11.8 mg of
17:0 in 2.36 mL of methanol.
3) 50 μL plasma sample + 5 μL Standard (5 mg/mL) + 1 mL BHT (100 μg/mL),
vortex.
4) Move to a glass tube, add 1 mL of distilled H2O, vortex.
5) Centrifuge at 2,000 rpm for 10 min at room temperature.
6) Take chloroform (bottom) phase to a reaction tube.
7) Dry with N2.
8) Add 100 μL of chloroform to dissolve sample.
9) Add 1 mL of boron trifluoride-methanol solution (BF3).
10) Incubate at 55 °C overnight.
11) Move to a glass tube and add 1mL of distilled H2O and 1mL of chloroform,
vortex.
12) Centrifuge at 2,000 rpm for 10 min at room temperature.
13) Take chloroform (bottom) phase to a fresh glass tube.
14) Dry with N2.
15) Add 500 μL of chloroform, shake, and transfer to a brown glass bottle, seal.
16) Plasma fatty acids profile was determined by gas chromatography by Dr.
Xiang-an Li at the Department of Pediatrics, University of Kentucky.
18. Ethoxyresorufin-o-deethylase (EROD) assay


Preparing stock solutions
1) Resorufin (RR, 50 μM) in methanol.
•

Dissolve 0.0587 g of RR in 5 mL of methanol to get 50 mM of RR.

•

Make a 1:1000 dilution of the RR (50 mM) with methanol to get 50 μM of
RR.
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•

Store at -20 °C in brown bottle with lid wrapped in parafilm.

2) Fluorescamine (0.6 mg/mL) in acetone.
•

Dissolve 30 mg of fluorescamine in 50 mL of acetone.

•

Store at -20 °C in brown bottle with lid wrapped in parafilm

3) 7-ethoxyresorufin (7ER, saturated) in methanol.
•

Add a few crystals of 7ER to 2 mL of methanol, warm with hot water,
vortex and settle. A saturated methanol solution of 7ER is around 400
μM.

•

Make triplicate 1:100 dilutions in PBS (e.g. 10 μL 7ER + 990 μL of PBS);
read absorbance of each dilution at 482 nm (A482).

•

Determine the concentration of 7ER using the equation: Con7ER (mM) =
A482 × 100 / E*.
* E (excitation coefficient) = 22.5 mM-1 cm-1.

•

Store at -20 °C in brown bottle with lid wrapped in parafilm.

4) BSA (2 mg/mL) in PBS.



•

Dissolve 20 mg of BSA in 10 mL of PBS.

•

Make aliquots and store at -20 °C.

Preparing working solutions
1) RR (15 μM): 150 μL of 50 μM RR + 350 μL of PBS.
2) 7ER (9.4 μM): make a working solution using methanol according the
concentration of the stock solution.
3) Warm up the PBS to 37 °C.



Preparing the 48-well standard plate
Pipette the following to the standard wells (Table II):
1) PBS: 135, 124, 114, 93, 71, 50 μL per well.
2) BSA (2 mg/mL): 0, 10, 20, 40, 60, 80 μL per well, corresponding to 0, 20, 40,
80, 120,160 μg per well.
3) RR (15 μM): 0, 0.5, 1, 2, 4, 5 μL per well, corresponding to 0, 7.5, 15, 30, 60,
75 pmol per well.
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Table II. Preparation of 48-well standard plate for EROD assay
PBS 135μl

PBS 135μl PBS 135μl

PBS 135μl

PBS 135μl

PBS 135μl

PBS 135μl

PBS 135μl

BSA 0μl

BSA 0μl

BSA 0μl

BSA 0μl

BSA 0μl

BSA 0μl

BSA 0μl

BSA 0μl

RR 0μl

RR 0μl

RR 0μl

RR 0μl

RR 0μl

RR 0μl

RR 0μl

RR 0μl

PBS 124μl

PBS 124μl PBS 124μl

PBS 124μl

PBS 124μl

PBS 124μl

PBS 124μl

PBS 124μl

BSA 10μl

BSA 10μl

BSA 10μl

BSA 10μl

BSA 10μl

BSA 10μl

BSA 10μl

BSA 10μl

RR 0.5μl

RR 0.5μl

RR 0.5μl

RR 0.5μl

RR 0.5μl

RR 0.5μl

RR 0.5μl

RR 0.5μl

PBS 114μl

PBS 114μl PBS 114μl

PBS 114μl

PBS 114μl

PBS 114μl

PBS 114μl

PBS 114μl

BSA 20μl

BSA 20μl

BSA 20μl

BSA 20μl

BSA 20μl

BSA 20μl

BSA 20μl

BSA 20μl

RR 1μl

RR 1μl

RR 1μl

RR 1μl

RR 1μl

RR 1μl

RR 1μl

RR 1μl

PBS 93μl

PBS 93μl

PBS 93μl

PBS 93μl

PBS 93μl

PBS 93μl

PBS 93μl

PBS 93μl

BSA 40μl

BSA 40μl

BSA 40μl

BSA 40μl

BSA 40μl

BSA 40μl

BSA 40μl

BSA 40μl

RR 2μl

RR 2μl

RR 2μl

RR 2μl

RR 2μl

RR 2μl

RR 2μl

RR 2μl

PBS 71μl

PBS 71μl

PBS 71μl

PBS 71μl

PBS 71μl

PBS 71μl

PBS 71μl

PBS 71μl

BSA 60μl

BSA 60μl

BSA 60μl

BSA 60μl

BSA 60μl

BSA 60μl

BSA 60μl

BSA 60μl

RR 4μl

RR 4μl

RR 4μl

RR 4μl

RR 4μl

RR 4μl

RR 4μl

RR 4μl

PBS 50μl

PBS 50μl

PBS 50μl

PBS 50μl

PBS 50μl

PBS 50μl

PBS 50μl

PBS 50μl

BSA 80μl

BSA 80μl

BSA 80μl

BSA 80μl

BSA 80μl

BSA 80μl

BSA 80μl

BSA 80μl

RR 5μl

RR 5μl

RR 5μl

RR 5μl

RR 5μl

RR 5μl

RR 5μl

RR 5μl



Preparing the 48-well cell plates
1) Remove exposure media from the cells.
2) Rinse the cells with 300 μL of PBS, and replace with 135 μL of PBS.



Reaction and Reading
1) Add 50 μL of 7ER working solution to all standard and cells wells
2) Place plate immediately into a Cytofluor 4000 plate reader (PE Biosystems,
Foster City, CA) and start reading (measuring EROD).
•

Program for the plate reader:
Excitation: 530 nm; Emission: 590 nm.
Run 10 cycles
Sensitivity: choose 15 or 16.
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On the Cytofluor choose 2 scans/cycle, gains of 50 and 60, and 3
reads/well.
3) Go to kinetics menu on Cytofluor and check for a linear rate. The reaction
should be linear for the first 10 to 15 minutes. Save files to Excel.
4) Remove the plate from the plate reader and add 100 μL of fluorescamine (0.6
mg/mL) to all wells. This will stop the reaction and develops the protein
signal.
5) Create a new file for the protein measurements
•

Program for the plate reader:
Excitation: 409 nm; Emission: 460 nm.
Sensitivity: same as used for measuring EROD



Calculations
1) Get the following parameters for each well:
•

Slope of EROD

•

Protein amount

•

Slope/Protein

2) Average of replicate wells = AFU*/min/mg
*AFU, absorbance fluorescence units
3) Convert to mole numbers of RR:
(AFU/min/mg)/(AFU/pmoles RR) = pmol/min/mg
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Additional data

350

a

300

iNOS mRNA

250
200
150
b
100
50
0
0 Zn / LF

30 Zn / LF

Figure I. Effect of zinc status on iNOS gene expression in abdominal aorta of low-fat
diet fed LDL-R-/- mice.
The vertical axis represents relative units, calculated as the ratio of the copy number of
iNOS over the copy number of 18S rRNA, the endogenous control. Values are means ±
SEM, n = 6-7. Means without a common letter differ (a > b), P < 0.05.
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0.5
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RSG

MT1 mRNA

0.4

P -values
0.027
0.935
0.005

0.3
0.2
0.1
0.0
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0 Zn + RSG

30 Zn

30 Zn + RSG

Figure II. Effects of dietary zinc status and rosiglitazone on MT1 mRNA expression
in LDL-R-/- mice.
The vertical axis represents relative units, calculated as the ratio of the copy number of
MT1 over the copy number of β-actin, the endogenous control. Values are means ±
SEM, n = 7-10. Zn × RSG interaction was not significant (P > 0.05).
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Figure III. Effects of dietary zinc status and rosiglitazone on PPARγ gene expression
in LDL-R-/- mice.
The vertical axis represents relative units, calculated as the ratio of the copy number of
PPARγ over the copy number of β-actin, the endogenous control. Values are means ±
SEM, n = 7-9. Zn × RSG interaction was not significant (P > 0.05).
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EROD (pmol/min/mg)

100
80
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40
20
0
0

0.0004

0.004

0.04

0.4

4

8

PCB77 (μ M)

Figure IV. Dose-response relationship between PCB77 and CYP1A activity in
vascular endothelial cells*.
CYP1A activity was measured by EROD assay. Endothelial cells were exposed to
increasing concentrations of PCB77 (0, 0.0004, 0.004, 0.04, 0.4, 4, and 8 μM) for 24
hours. n = 8.
* The data were contributed by Dr. Xabier Arzuaga at the University of Kentucky
Molecular and Cell Nutrition Laboratory (Hennig’s laboratory).
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Figure V. Effects of cellular zinc status and PCB77 on the AhR protein expression
in vascular endothelial cells.
Similar to Figure 5.1, endothelial cells were exposed to vehicle control, TPEN, PCB77
(3.4 μM), TPEN plus PCB77, or TPEN with zinc supplementation (20 μM) plus PCB77
for 24 hours. The values are ratios of the densitometric units of AhR over those of βActin. Bars with different letters (a, b) are statistically different from each other (P <
0.05). n = 3. The gel data are a representative of the typical outcome of three repeated
western blot experiments.

114

120

ERα Protein

100
80
60
40
20
0
Control

TPEN

TPEN + Zn

Zn

ERα
β-actin

Figure VI. Zinc deficiency does not affect estrogen receptor (ER)α protein
expression in vascular endothelial cells.
Endothelial cells were exposed to vehicle control (ethanol, 0.075 %), TPEN (1.5 μM),
TPEN (1.5 μM) plus Zn (20 μM), or Zn (20 μM) for 24 h. ERα protein expression was
measured by Western blot. The values are ratios of the densitometric units of ERα over
those of β-actin, the endogenous control, expressed as percentage of control. Values are
means ± SEM, n = 4. The gel data are a representative of the typical outcome of four
repeated Western Blot experiments.
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mRNA Expression
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Figure VII. Zinc deficiency compromises PCB77-induced VCAM-1 and E-selectin
mRNA expression in vascular endothelial cells
Similar to Figure 5.1, endothelial cells were exposed to vehicle control, TPEN, PCB77
(3.4 μM), TPEN plus PCB77, or TPEN with zinc supplementation (20 μM) plus PCB77
for 24 hours. The values are ratios of the densitometric units of VCAM-1 or E-selectin
over those of β-actin. Bars with different letters (a, b, c for VCAM-1 and a’, b’, c’, d’ for
E-selectin) are statistically different from each other (P < 0.05). n = 3. The gel data are a
representative of the typical outcome of three repeated RT-PCR experiments.
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